Characteristic, Regulation and Targeting Strategies of Cancer Stem Cells and Their Niche in Digestive System Tumors

Abstract

Digestive system tumor, including esophageal tumor, gastric tumor, intestinal tumor, liver tumor, pancreatic tumor, and cholangiocarcinoma, are the most common tumors worldwide and serve as a major cause of tumor-related death. Cancer stem cells (CSCs) are a small group of cells in tumors that harbor self-renewal, differentiation abilities, playing a crucial role in tumor initiation, progression, metastasis, and are supposed to be the fundamental cause of tumor recurrence after conventional treatment. A comprehensive understanding and targeting of CSCs is the key to overcoming tumors. In this review, focusing on digestive system tumors, we summarize the characteristics of CSCs, review the intracellular mechanisms that regulate self-renewal and functional maintenance of CSCs, including stemness pathways, transcription and epigenetic regulation, metabolic regulation, and noncoding RNAs, and demonstrate microenvironmental regulation and systemic regulation of CSCs at molecular and cellular levels. Finally, we summarize recent advances in tumor therapy with CSC targeting and their niche remodeling. These research progress on CSCs in digestive system tumors provide crucial insights into the occurrence, development, drug resistance, recurrence and metastasis of tumors, and offers new targeted treatment strategies for defeating tumors.

Keywords

cancer stem cells / digestive system tumors / microenvironmental regulation / targeted therapy

References

[1] R. L. Siegel, K. D. Miller, N. S. Wagle, and A. Jemal, “Cancer Statistics, 2023,” CA: A Cancer Journal for Clinicians 73, no. 1 (2023): 17–48.

[2] F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229–263.

[3] K. D. Miller, L. Nogueira, T. Devasia, et al., “Cancer Treatment and Survivorship Statistics, 2022,” CA: A Cancer Journal for Clinicians 72, no. 5 (2022): 409–436.

[4] U. Anand, A. Dey, A. K. S. Chandel, et al., “Cancer Chemotherapy and Beyond: Current Status, Drug Candidates, Associated Risks and Progress in Targeted Therapeutics,” Genes & Diseases 10, no. 4 (2023): 1367–1401.

[5] K. Pantel and C. Alix-Panabières, “Liquid Biopsy and Minimal Residual Disease—Latest Advances and Implications for Cure,” Nature Reviews Clinical Oncology 16, no. 7 (2019): 409–424.

[6] D. Kotani, E. Oki, Y. Nakamura, et al., “Molecular Residual Disease and Efficacy of Adjuvant Chemotherapy in Patients With Colorectal Cancer,” Nature Medicine 29, no. 1 (2023): 127–134.

[7] E. Batlle and H. Clevers, “Cancer Stem Cells Revisited,” Nature Medicine 23, no. 10 (2017): 1124–1134.

[8] T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, “Stem Cells, Cancer, and Cancer Stem Cells,” Nature 414, no. 6859 (2001): 105–111.

[9] H. Easwaran, H.-C. Tsai, and S. B. Baylin, “Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-Like States, and Drug Resistance,” Molecular Cell 54, no. 5 (2014): 716–727.

[10] G. van Niekerk, L. M. Davids, S. M. Hattingh, and A. M. Engelbrecht, “Cancer Stem Cells: A Product of Clonal Evolution?,” International Journal of Cancer 140, no. 5 (2017): 993–999.

[11] P. C. W. Davies and C. H. Lineweaver, “Cancer Tumors as Metazoa 1.0: Tapping Genes of Ancient Ancestors,” Physical Biology 8, no. 1 (2011): 015001.

[12] K. Eun, S. W. Ham, and H. Kim, “Cancer Stem Cell Heterogeneity: Origin and New Perspectives on CSC Targeting,” BMB Reports 50, no. 3 (2017): 117–125.

[13] N. Barker, J. H. van Es, J. Kuipers, et al., “Identification of Stem Cells in Small Intestine and Colon by Marker Gene LGR5,” Nature 449, no. 7165 (2007): 1003–1007.

[14] N. Barker, R. A. Ridgway, J. H. van Es, et al., “Crypt Stem Cells as the Cells-of-Origin of Intestinal Cancer,” Nature 457, no. 7229 (2009): 608–611.

[15] S. H. Tan, Y. Swathi, S. Tan, et al., “AQP5 Enriches for Stem Cells and Cancer Origins in the Distal Stomach,” Nature 578, no. 7795 (2020): 437–443.

[16] Y. Hayakawa, H. Nakagawa, A. K. Rustgi, J. Que, and T. C. Wang, “Stem Cells and Origins of Cancer in the Upper Gastrointestinal Tract,” Cell Stem Cell 28, no. 8 (2021): 1343–1361.

[17] B. Wang, L. Zhao, M. Fish, C. Y. Logan, and R. Nusse, “Self-Renewing Diploid Axin2⁺ Cells Fuel Homeostatic Renewal of the Liver,” Nature 524, no. 7564 (2015): 180–185.

[18] G. He, D. Dhar, H. Nakagawa, et al., “Identification of Liver Cancer Progenitors Whose Malignant Progression Depends on Autocrine IL-6 Signaling,” Cell 155, no. 2 (2013): 384–396.

[19] M. P. Verhagen, R. Joosten, M. Schmitt, et al., “Non-Stem Cell Lineages as an Alternative Origin of Intestinal Tumorigenesis in the Context of Inflammation,” Nature Genetics 56, no. 7 (2024): 1456–1467.

[20] S. Schwitalla, A. A. Fingerle, P. Cammareri, et al., “Intestinal Tumorigenesis Initiated by Dedifferentiation and Acquisition of Stem-Cell-Like Properties,” Cell 152, no. 1–2 (2013): 25–38.

[21] T. Matsumoto, A. Takai, Y. Eso, et al., “Proliferating EpCAM-Positive Ductal Cells in the Inflamed Liver Give Rise to Hepatocellular Carcinoma,” Cancer Research 77, no. 22 (2017): 6131–6143.

[22] C. H. Ang, S. H. Hsu, F. Guo, et al., “LGR5⁺ Pericentral Hepatocytes Are Self-Maintained in Normal Liver Regeneration and Susceptible to Hepatocarcinogenesis,” Proceedings of the National Academy of Sciences 116, no. 39 (2019): 19530–19540.

[23] W. Cao, M. Li, J. Liu, et al., “LGR5 Marks Targetable Tumor-Initiating Cells in Mouse Liver Cancer,” Nature Communications 11, no. 1 (2020): 1961.

[24] M. Biton, A. L. Haber, N. Rogel, et al., “T Helper Cell Cytokines Modulate Intestinal Stem Cell Renewal and Differentiation,” Cell 175, no. 5 (2018): 1307–1320.

[25] E. Gil Vazquez, N. Nasreddin, G. N. Valbuena, et al., “Dynamic and Adaptive Cancer Stem Cell Population Admixture in Colorectal Neoplasia,” Cell Stem Cell 29, no. 8 (2022): 1213–1228.

[26] A. Fumagalli, K. C. Oost, L. Kester, et al., “Plasticity of LGR5-Negative Cancer Cells Drives Metastasis in Colorectal Cancer,” Cell Stem Cell 26, no. 4 (2020): 569–578.

[27] F. de Sousa e Melo, A. V. Kurtova, J. M. Harnoss, et al., “A Distinct Role for LGR5⁺ Stem Cells in Primary and Metastatic Colon Cancer,” Nature 543, no. 7647 (2017): 676–680.

[28] M. Shimokawa, Y. Ohta, S. Nishikori, et al., “Visualization and Targeting of LGR5⁺ Human Colon Cancer Stem Cells,” Nature 545, no. 7653 (2017): 187–192.

[29] J. Houghton, C. Stoicov, S. Nomura, et al., “Gastric Cancer Originating From Bone Marrow-Derived Cells,” Science 306, no. 5701 (2004): 1568–1571.

[30] S. Takaishi, T. Okumura, and T. C. Wang, “Gastric Cancer Stem Cells,” Journal of Clinical Oncology 26, no. 17 (2008): 2876–2882.

[31] X. Wang, H. Willenbring, Y. Akkari, et al., “Cell Fusion Is the Principal Source of Bone-Marrow-Derived Hepatocytes,” Nature 422, no. 6934 (2003): 897–901.

[32] A. Z. Rizvi, J. R. Swain, P. S. Davies, et al., “Bone Marrow-Derived Cells Fuse With Normal and Transformed Intestinal Stem Cells,” Proceedings of the National Academy of Sciences 103, no. 16 (2006): 6321–6325.

[33] H. J. Snippert, L. G. van der Flier, T. Sato, et al., “Intestinal Crypt Homeostasis Results From Neutral Competition Between Symmetrically Dividing LGR5 Stem Cells,” Cell 143, no. 1 (2010): 134–144.

[34] C. Lopez-Garcia, A. M. Klein, B. D. Simons, and D. J. Winton, “Intestinal Stem Cell Replacement Follows a Pattern of Neutral Drift,” Science 330, no. 6005 (2010): 822–825.

[35] Q. Chen, K. Weng, M. Lin, et al., “SOX9 Modulates the Transformation of Gastric Stem Cells Through Biased Symmetric Cell Division,” Gastroenterology 164, no. 7 (2023): 1119–1136.

[36] W. Chang, H. Wang, W. Kim, et al., “Hormonal Suppression of Stem Cells Inhibits Symmetric Cell Division and Gastric Tumorigenesis,” Cell Stem Cell 26, no. 5 (2020): 739–754.

[37] S. Majumdar and S.-T. Liu, “Cell Division Symmetry Control and Cancer Stem Cells,” AIMS Molecular Science 7, no. 2 (2020): 82–101.

[38] J. Beumer and H. Clevers, “Hallmarks of Stemness in Mammalian Tissues,” Cell Stem Cell 31, no. 1 (2024): 7–24.

[39] A. Miranda, P. T. Hamilton, A. W. Zhang, et al., “Cancer Stemness, Intratumoral Heterogeneity, and Immune Response Across Cancers,” Proceedings of the National Academy of Sciences 116, no. 18 (2019): 9020–9029.

[40] V. M.-Y. Wang, R. M. M. Ferreira, J. Almagro, et al., “CD9 Identifies Pancreatic Cancer Stem Cells and Modulates Glutamine Metabolism to Fuel Tumour Growth,” Nature Cell Biology 21, no. 11 (2019): 1425–1435.

[41] L. Zhou, K. H. Yu, T. L. Wong, et al., “Lineage Tracing and Single-Cell Analysis Reveal Proliferative Prom1+ Tumour-Propagating Cells and Their Dynamic Cellular Transition During Liver Cancer Progression,” Gut 71, no. 8 (2022): 1656–1668.

[42] A. G. Schepers, H. J. Snippert, D. E. Stange, et al., “Lineage Tracing Reveals LGR5⁺ Stem Cell Activity in Mouse Intestinal Adenomas,” Science 337, no. 6095 (2012): 730–735.

[43] Z. Huang, T. Wu, A. Y. Liu, and G. Ouyang, “Differentiation and Transdifferentiation Potentials of Cancer Stem Cells,” Oncotarget 6, no. 37 (2015): 39550–39563.

[44] Y.-Q. Xiong, H.-C. Sun, W. Zhang, et al., “Human Hepatocellular Carcinoma Tumor-Derived Endothelial Cells Manifest Increased Angiogenesis Capability and Drug Resistance Compared With Normal Endothelial Cells,” Clinical Cancer Research 15, no. 15 (2009): 4838–4846.

[45] B. Bussolati, S. Bruno, C. Grange, U. Ferrando, and G. Camussi, “Identification of a Tumor-Initiating Stem Cell Population in Human Renal Carcinomas,” FASEB Journal 22, no. 10 (2008): 3696–3705.

[46] G. Hassan and M. Seno, “Blood and Cancer: Cancer Stem Cells as Origin of Hematopoietic Cells in Solid Tumor Microenvironments,” Cells 9, no. 5 (2020): 1293.

[47] A. T. Vessoni, E. C. Filippi-Chiela, G. Lenz, and L. F. Z. Batista, “Tumor Propagating Cells: Drivers of Tumor Plasticity, Heterogeneity, and Recurrence,” Oncogene 39, no. 10 (2020): 2055–2068.

[48] R. Li, X. Liu, X. Huang, et al., “Single-Cell Transcriptomic Analysis Deciphers Heterogenous Cancer Stem-Like Cells in Colorectal Cancer and Their Organ-Specific Metastasis,” Gut 73, no. 3 (2024): 470–484.

[49] H. Zheng, Y. Pomyen, M. O. Hernandez, et al., “Single-Cell Analysis Reveals Cancer Stem Cell Heterogeneity in Hepatocellular Carcinoma,” Hepatology 68, no. 1 (2018): 127–140.

[50] D. W.-H. Ho, Y.-M. Tsui, K. M.-F. Sze, et al., “Single-Cell Transcriptomics Reveals the Landscape of Intra-Tumoral Heterogeneity and Stemness-Related Subpopulations in Liver Cancer,” Cancer Letters 459 (2019): 176–185.

[51] M. Ramos Zapatero, A. Tong, J. W. Opzoomer, et al., “Trellis Tree-Based Analysis Reveals Stromal Regulation of Patient-Derived Organoid Drug Responses,” Cell 186, no. 25 (2023): 5606–5619.

[52] J.-R. Lin, S. Wang, S. Coy, et al., “Multiplexed 3D Atlas of State Transitions and Immune Interaction in Colorectal Cancer,” Cell 186, no. 2 (2023): 363–381.

[53] W. Guo, Y.-F. Sun, M.-N. Shen, et al., “Circulating Tumor Cells With Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular Carcinoma,” Clinical Cancer Research 24, no. 9 (2018): 2203–2213.

[54] Z. F. Yang, P. Ngai, D. W. Ho, et al., “Identification of Local and Circulating Cancer Stem Cells in Human Liver Cancer,” Hepatology 47, no. 3 (2008): 919–928.

[55] S. Liu, N. Li, X. Yu, et al., “Expression of Intercellular Adhesion Molecule 1 by Hepatocellular Carcinoma Stem Cells and Circulating Tumor Cells,” Gastroenterology 144, no. 5 (2013): 1031–1041.

[56] Y.-F. Sun, Y. Xu, X.-R. Yang, et al., “Circulating Stem Cell-Like Epithelial Cell Adhesion Molecule-Positive Tumor Cells Indicate Poor Prognosis of Hepatocellular Carcinoma After Curative Resection,” Hepatology 57, no. 4 (2013): 1458–1468.

[57] C. Kantara, M. R. O'Connell, G. Luthra, et al., “Methods for Detecting Circulating Cancer Stem Cells (CCSCs) as a Novel Approach for Diagnosis of Colon Cancer Relapse/Metastasis,” Laboratory Investigation 95, no. 1 (2015): 100–112.

[58] W. Yi-Wen, L. Long-Long, L. Ming, L. Hao, and H. Kong-Wang, “Stem Cell-Like Circulating Tumor Cells Indicate Poor Prognosis in Gastric Cancer,” Archives of Medical Science 18, no. 5 (2022): 1297–1307.

[59] X.-L. Ma, M.-N. Shen, B. Hu, et al., “CD73 Promotes Hepatocellular Carcinoma Progression and Metastasis via Activating PI3K/AKT Signaling by Inducing Rap1-Mediated Membrane Localization of P110β and Predicts Poor Prognosis,” Journal of Hematology & Oncology 12, no. 1 (2019): 37.

[60] X.-L. Ma, B. Hu, W.-G. Tang, et al., “CD73 Sustained Cancer-Stem-Cell Traits by Promoting SOX9 Expression and Stability in Hepatocellular Carcinoma,” Journal of Hematology & Oncology 13, no. 1 (2020): 11.

[61] M. Nakano, R. Taguchi, Y. Kikushige, et al., “RHAMM Marks Proliferative Subpopulation of Human Colorectal Cancer Stem Cells,” Cancer Science 114, no. 7 (2023): 2895–2906.

[62] S. Choi, D. Wang, X. Chen, et al., “Function and Clinical Relevance of RHAMM Isoforms in Pancreatic Tumor Progression,” Molecular Cancer 18, no. 1 (2019): 92.

[63] M. Huch, C. Dorrell, S. F. Boj, et al., “In Vitro Expansion of Single LGR5⁺ Liver Stem Cells Induced by Wnt-Driven Regeneration,” Nature 494, no. 7436 (2013): 247–250.

[64] Y. Ohta, M. Fujii, S. Takahashi, et al., “Cell–Matrix Interface Regulates Dormancy in Human Colon Cancer Stem Cells,” Nature 608, no. 7924 (2022): 784–794.

[65] S. J. A. Buczacki, H. I. Zecchini, A. M. Nicholson, et al., “Intestinal Label-Retaining Cells Are Secretory Precursors Expressing LGR5,” Nature 495, no. 7439 (2013): 65–69.

[66] K. C. Roche, A. D. Gracz, X. F. Liu, V. Newton, H. Akiyama, and S. T. Magness, “SOX9 Maintains Reserve Stem Cells and Preserves Radioresistance in Mouse Small Intestine,” Gastroenterology 149, no. 6 (2015): 1553–1563.

[67] K. M. Braun and F. M. Watt, “Epidermal Label-Retaining Cells: Background and Recent Applications,” Journal of Investigative Dermatology Symposium Proceedings 9, no. 3 (2004): 196–201.

[68] N. Moore and S. Lyle, “Quiescent, Slow-Cycling Stem Cell Populations in Cancer: A Review of the Evidence and Discussion of Significance,” Journal of Oncology 2011 (2011): 396076.

[69] A. Álvarez-Varela, L. Novellasdemunt, F. M. Barriga, et al., “Mex3a Marks Drug-Tolerant Persister Colorectal Cancer Cells That Mediate Relapse After Chemotherapy,” Nature Cancer 3, no. 9 (2022): 1052–1070.

[70] S. Basu, Y. Dong, R. Kumar, C. Jeter, and D. G. Tang, “Slow-Cycling (Dormant) Cancer Cells in Therapy Resistance, Cancer Relapse and Metastasis,” Seminars in Cancer Biology 78 (2022): 90–103.

[71] A. J. Wiecek, S. J. Cutty, D. Kornai, et al., “Genomic Hallmarks and Therapeutic Implications of G0 Cell Cycle Arrest in Cancer,” Genome Biology 24, no. 1 (2023): 128.

[72] E. Cuesta-Borràs, C. Salvans, O. Arqués, et al., “DPPA3–HIF1α Axis Controls Colorectal Cancer Chemoresistance by Imposing a Slow Cell-Cycle Phenotype,” Cell Reports 42, no. 8 (2023): 112927.

[73] J. He, Z. Qiu, J. Fan, X. Xie, Q. Sheng, and X. Sui, “Drug Tolerant Persister Cell Plasticity in Cancer: A Revolutionary Strategy for More Effective Anticancer Therapies,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 209.

[74] Y. Pu, L. Li, H. Peng, et al., “Drug-Tolerant Persister Cells in Cancer: The Cutting Edges and Future Directions,” Nature Reviews Clinical Oncology 20, no. 11 (2023): 799–813.

[75] Y. Li, Z. Wang, J. A. Ajani, and S. Song, “Drug Resistance and Cancer Stem Cells,” Cell Communication and Signaling 19, no. 1 (2021): 19.

[76] D. Raha, T. R. Wilson, J. Peng, et al., “The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation,” Cancer Research 74, no. 13 (2014): 3579–3590.

[77] B. A. Mengistu, T. Tsegaw, Y. Demessie, et al., “Comprehensive Review of Drug Resistance in Mammalian Cancer Stem Cells: Implications for Cancer Therapy,” Cancer Cell International 24, no. 1 (2024): 406.

[78] G. D. Guler, C. A. Tindell, R. Pitti, et al., “Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations From Lethal Drug Exposure,” Cancer Cell 32, no. 2 (2017): 221–237.

[79] A. Pérez-González, K. Bévant, and C. Blanpain, “Cancer Cell Plasticity During Tumor Progression, Metastasis and Response to Therapy,” Nature Cancer 4, no. 8 (2023): 1063–1082.

[80] J.-J. Loh and S. Ma, “Hallmarks of Cancer Stemness,” Cell Stem Cell 31, no. 5 (2024): 617–639.

[81] M. Todaro, M. Gaggianesi, V. Catalano, et al., “CD44v6 Is a Marker of Constitutive and Reprogrammed Cancer Stem Cells Driving Colon Cancer Metastasis,” Cell Stem Cell 14, no. 3 (2014): 342–356.

[82] U. Jadhav, M. Saxena, N. K. O'Neill, et al., “Dynamic Reorganization of Chromatin Accessibility Signatures During Dedifferentiation of Secretory Precursors into LGR5⁺ Intestinal Stem Cells,” Cell Stem Cell 21, no. 1 (2017): 65–77.

[83] P. W. Tetteh, O. Basak, H. F. Farin, et al., “Replacement of Lost LGR5-Positive Stem Cells Through Plasticity of Their Enterocyte-Lineage Daughters,” Cell Stem Cell 18, no. 2 (2016): 203–213.

[84] T.-H. Kim, F. Li, I. Ferreiro-Neira, et al., “Broadly Permissive Intestinal Chromatin Underlies Lateral Inhibition and Cell Plasticity,” Nature 506, no. 7489 (2014): 511–515.

[85] Y. M. Nusse, A. K. Savage, P. Marangoni, et al., “Parasitic Helminths Induce Fetal-Like Reversion in the Intestinal Stem Cell Niche,” Nature 559, no. 7712 (2018): 109–113.

[86] X. Qin, F. Cardoso Rodriguez, J. Sufi, P. Vlckova, J. Claus, and C. J. Tape, “An Oncogenic Phenoscape of Colonic Stem Cell Polarization,” Cell 186, no. 25 (2023): 5554–5568.

[87] L. Solé, T. Lobo-Jarne, D. Álvarez-Villanueva, et al., “P53 Wild-Type Colorectal Cancer Cells That Express a Fetal Gene Signature Are Associated With Metastasis and Poor Prognosis,” Nature Communications 13, no. 1 (2022): 2866.

[88] S. Su, J. Chen, H. Yao, et al., “CD10⁺GPR77⁺ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness,” Cell 172, no. 4 (2018): 841–856.

[89] L. Beziaud, C. M. Young, A. M. Alonso, M. Norkin, A. R. Minafra, and J. Huelsken, “IFNγ-Induced Stem-Like State of Cancer Cells as a Driver of Metastatic Progression Following Immunotherapy,” Cell Stem Cell 30, no. 6 (2023): 818–831.

[90] M. Musella, A. Guarracino, N. Manduca, et al., “Type I IFNs Promote Cancer Cell Stemness by Triggering the Epigenetic Regulator KDM1B,” Nature Immunology 23, no. 9 (2022): 1379–1392.

[91] C. Wu, T. Rakhshandehroo, H. I. Wettersten, et al., “Pancreatic Cancer Cells Upregulate LPAR4 in Response to Isolation Stress to Promote an ECM-Enriched Niche and Support Tumour Initiation,” Nature Cell Biology 25, no. 2 (2023): 309–322.

[92] P. E. Saw, Q. Liu, P.-P. Wong, and E. Song, “Cancer Stem Cell Mimicry for Immune Evasion and Therapeutic Resistance,” Cell Stem Cell 31, no. 8 (2024): 1101–1112.

[93] T. Sharif, E. Martell, C. Dai, et al., “Autophagic Homeostasis Is Required for the Pluripotency of Cancer Stem Cells,” Autophagy 13, no. 2 (2017): 264–284.

[94] K. Liu, J. Lee, J. Y. Kim, et al., “Mitophagy Controls the Activities of Tumor Suppressor P53 to Regulate Hepatic Cancer Stem Cells,” Molecular Cell 68, no. 2 (2017): 281–292.

[95] M. El Hout, L. Dos Santos, A. Hamaï, and M. Mehrpour, “A Promising New Approach to Cancer Therapy: Targeting Iron Metabolism in Cancer Stem Cells,” Seminars in Cancer Biology 53 (2018): 125–138.

[96] Q. Zhao, H. Zong, P. Zhu, et al., “Crosstalk Between Colorectal CSCs and Immune Cells in Tumorigenesis, and Strategies for Targeting Colorectal CSCs,” Experimental Hematology & Oncology 13, no. 1 (2024): 6.

[97] J. M. Perry, F. Tao, A. Roy, et al., “Overcoming Wnt-β-Catenin Dependent Anticancer Therapy Resistance in Leukaemia Stem Cells,” Nature Cell Biology 22, no. 6 (2020): 689–700.

[98] Y. Miao, H. Yang, J. Levorse, et al., “Adaptive Immune Resistance Emerges From Tumor-Initiating Stem Cells,” Cell 177, no. 5 (2019): 1172–1186.

[99] J. Beumer and H. Clevers, “Cell Fate Specification and Differentiation in the Adult Mammalian Intestine,” Nature Reviews Molecular Cell Biology 22, no. 1 (2021): 39–53.

[100] T.-L. Wong, J.-J. Loh, S. Lu, et al., “ADAR1-Mediated RNA Editing of SCD1 Drives Drug Resistance and Self-Renewal in Gastric Cancer,” Nature Communications 14, no. 1 (2023): 2861.

[101] K. Sehgal, A. Portell, E. V. Ivanova, et al., “Dynamic Single-Cell RNA Sequencing Identifies Immunotherapy Persister Cells Following PD-1 Blockade,” Journal of Clinical Investigation 131, no. 2 (2021): e135038.

[102] C. J. Tape, “Plastic Persisters: Revival Stem Cells in Colorectal Cancer,” Trends in Cancer 10, no. 3 (2024): 185–195.

[103] M. M. Gottesman, T. Fojo, and S. E. Bates, “Multidrug Resistance in Cancer: Role of ATP-Dependent Transporters,” Nature Reviews Cancer 2, no. 1 (2002): 48–58.

[104] M. Diehn, R. W. Cho, N. A. Lobo, et al., “Association of Reactive Oxygen Species Levels and Radioresistance in Cancer Stem Cells,” Nature 458, no. 7239 (2009): 780–783.

[105] Y. An and W. M. Ongkeko, “ABCG2: The Key to Chemoresistance in Cancer Stem Cells?,” Expert Opinion on Drug Metabolism & Toxicology 5, no. 12 (2009): 1529–1542.

[106] N. Haraguchi, T. Utsunomiya, H. Inoue, et al., “Characterization of a Side Population of Cancer Cells From Human Gastrointestinal System,” Stem Cells 24, no. 3 (2006): 506–513.

[107] T. Chiba, K. Kita, Y.-W. Zheng, et al., “Side Population Purified From Hepatocellular Carcinoma Cells Harbors Cancer Stem Cell-Like Properties,” Hepatology 44, no. 1 (2006): 240–251.

[108] T. Oka, T. Higa, O. Sugahara, D. Koga, S. Nakayama, and K. I. Nakayama, “Ablation of P57⁺ Quiescent Cancer Stem Cells Suppresses Recurrence After Chemotherapy of Intestinal Tumors,” Cancer Research 83, no. 9 (2023): 1393–1409.

[109] S. K. Kim, H. Kim, D. Lee, et al., “Reversing the Intractable Nature of Pancreatic Cancer by Selectively Targeting ALDH-High, Therapy-Resistant Cancer Cells,” PLoS One 8, no. 10 (2013): e78130.

[110] S. S. Dinavahi, C. G. Bazewicz, R. Gowda, and G. P. Robertson, “Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics,” Trends in Pharmacological Sciences 40, no. 10 (2019): 774–789.

[111] C. R. Arnold, J. Mangesius, I.-I. Skvortsova, and U. Ganswindt, “The Role of Cancer Stem Cells in Radiation Resistance,” Frontiers in Oncology 10 (2020): 164.

[112] S. Hoque, R. Dhar, R. Kar, et al., “Cancer Stem Cells (CSCs): Key Player of Radiotherapy Resistance and Its Clinical Significance,” Biomarkers 28, no. 2 (2023): 139–151.

[113] A. Sánchez-Danés, J.-C. Larsimont, M. Liagre, et al., “A Slow-Cycling LGR5 Tumour Population Mediates Basal Cell Carcinoma Relapse After Therapy,” Nature 562, no. 7727 (2018): 434–438.

[114] J. Wang, H. Yu, W. Dong, et al., “N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways,” Gastroenterology 164, no. 6 (2023): 990–1005.

[115] C. O. N. Leung, Y. Yang, R. W. H. Leung, et al., “Broad-Spectrum Kinome Profiling Identifies CDK6 Upregulation as a Driver of Lenvatinib Resistance in Hepatocellular Carcinoma,” Nature Communications 14, no. 1 (2023): 6699.

[116] X. Ma, K. Zhou, T. Yan, et al., “Calpain 2 Promotes Lenvatinib Resistance and Cancer Stem Cell Traits via Both Proteolysis-Dependent and Independent Approach in Hepatocellular Carcinoma,” Molecular Biomedicine 5 (2024): 74.

[117] D. Bayik and J. D. Lathia, “Cancer Stem Cell-Immune Cell Crosstalk in Tumour Progression,” Nature Reviews Cancer 21, no. 8 (2021): 526–536.

[118] B. J. Morrison, J. C. Steel, and J. C. Morris, “Reduction of MHC-I Expression Limits T-Lymphocyte-Mediated Killing of Cancer-Initiating Cells,” BMC Cancer 18, no. 1 (2018): 469.

[119] A. Volonté, T. Di Tomaso, M. Spinelli, et al., “Cancer-Initiating Cells From Colorectal Cancer Patients Escape From T Cell-Mediated Immunosurveillance In Vitro Through Membrane-Bound Il-4,” Journal of Immunology 192, no. 1 (2014): 523–532.

[120] X. He, S. E. Smith, S. Chen, et al., “Tumor-Initiating Stem Cell Shapes Its Microenvironment Into an Immunosuppressive Barrier and Pro-Tumorigenic Niche,” Cell Reports 36, no. 10 (2021): 109674.

[121] J. Massagué and K. Ganesh, “Metastasis-Initiating Cells and Ecosystems,” Cancer Discovery 11, no. 4 (2021): 971–994.

[122] R. Pang, W. L. Law, A. C. Y. Chu, et al., “A Subpopulation of CD26⁺ Cancer Stem Cells With Metastatic Capacity in Human Colorectal Cancer,” Cell Stem Cell 6, no. 6 (2010): 603–615.

[123] A. Fatehullah, Y. Terakado, S. Sagiraju, et al., “A Tumour-Resident LGR5⁺ Stem-Cell-Like Pool Drives the Establishment and Progression of Advanced Gastric Cancers,” Nature Cell Biology 23, no. 12 (2021): 1299–1313.

[124] T. Shibue and R. A. Weinberg, “EMT, CSCs, and Drug Resistance: The Mechanistic Link and Clinical Implications,” Nature Reviews Clinical Oncology 14, no. 10 (2017): 611–629.

[125] Y. Li, L. Wang, L. Pappan, A. Galliher-Beckley, and J. Shi, “IL-1β Promotes Stemness and Invasiveness of Colon Cancer Cells Through Zeb1 Activation,” Molecular Cancer 11 (2012): 87.

[126] Z. Chen, T. Lu, L. Huang, et al., “Circular RNA Cia-MAF Drives Self-Renewal and Metastasis of Liver Tumor-Initiating Cells via Transcription Factor MAFF,” Journal of Clinical Investigation 131, no. 19 (2021): e148020.

[127] Z. Chen, J. Wu, B. Liu, et al., “Identification of Cis-HOX-HOXC10 Axis as a Therapeutic Target for Colorectal Tumor-Initiating Cells Without APC Mutations,” Cell Reports 36, no. 4 (2021): 109431.

[128] Z. Chen, Q. He, T. Lu, et al., “mcPGK1-Dependent Mitochondrial Import of PGK1 Promotes Metabolic Reprogramming and Self-Renewal of Liver TICs,” Nature Communications 14 (2023): 1121.

[129] Z. Chen, L. Huang, K. Wang, et al., “rtcisE2F Promotes the Self-Renewal and Metastasis of Liver Tumor-Initiating Cells via N6-Methyladenosine-Dependent E2F3/E2F6 mRNA Stability,” Science China Life Sciences 65, no. 9 (2022): 1840–1854.

[130] J. Dong, J. Li, Y. Li, Z. Ma, Y. Yu, and C.-Y. Wang, “Transcriptional Super-Enhancers Control Cancer Stemness and Metastasis Genes in Squamous Cell Carcinoma,” Nature Communications 12, no. 1 (2021): 3974.

[131] K. Ganesh and J. Massagué, “Targeting Metastatic Cancer,” Nature Medicine 27, no. 1 (2021): 34–44.

[132] K. Ganesh, H. Basnet, Y. Kaygusuz, et al., “L1CAM Defines the Regenerative Origin of Metastasis-Initiating Cells in Colorectal Cancer,” Nature Cancer 1, no. 1 (2020): 28–45.

[133] A. Cañellas-Socias, C. Cortina, X. Hernando-Momblona, et al., “Metastatic Recurrence in Colorectal Cancer Arises From Residual EMP1⁺ Cells,” Nature 611, no. 7936 (2022): 603–613.

[134] M. C. Heinz, N. A. Peters, K. C. Oost, et al., “Liver Colonization by Colorectal Cancer Metastases Requires YAP-Controlled Plasticity at the Micrometastatic Stage,” Cancer Research 82, no. 10 (2022): 1953–1968.

[135] T. Lapidot, C. Sirard, J. Vormoor, et al., “A Cell Initiating Human Acute Myeloid Leukaemia After Transplantation into SCID Mice,” Nature 367, no. 6464 (1994): 645–648.

[136] D. Bonnet and J. E. Dick, “Human Acute Myeloid Leukemia Is Organized as a Hierarchy That Originates From a Primitive Hematopoietic Cell,” Nature Medicine 3, no. 7 (1997): 730–737.

[137] S. Saito, C.-C. Ku, K. Wuputra, et al., “Biomarkers of Cancer Stem Cells for Experimental Research and Clinical Application,” Journal of Personalized Medicine 12, no. 5 (2022): 715.

[138] S. Ma, K.-W. Chan, L. Hu, et al., “Identification and Characterization of Tumorigenic Liver Cancer Stem/Progenitor Cells,” Gastroenterology 132, no. 7 (2007): 2542–2556.

[139] N. Haraguchi, H. Ishii, K. Mimori, et al., “CD13 Is a Therapeutic Target in Human Liver Cancer Stem Cells,” Journal of Clinical Investigation 120, no. 9 (2010): 3326–3339.

[140] Z. F. Yang, D. W. Ho, M. N. Ng, et al., “Significance of CD90⁺ Cancer Stem Cells in Human Liver Cancer,” Cancer Cell 13, no. 2 (2008): 153–166.

[141] B. Terris, C. Cavard, and C. Perret, “EpCAM, a New Marker for Cancer Stem Cells in Hepatocellular Carcinoma,” Journal of Hepatology 52, no. 2 (2010): 280–281.

[142] Y. Wang, L. He, Y. Du, et al., “The Long Noncoding RNA lncTCF7 Promotes Self-Renewal of Human Liver Cancer Stem Cells Through Activation of Wnt Signaling,” Cell Stem Cell 16, no. 4 (2015): 413–425.

[143] L. Ricci-Vitiani, D. G. Lombardi, E. Pilozzi, et al., “Identification and Expansion of Human Colon-Cancer-Initiating Cells,” Nature 445, no. 7123 (2007): 111–115.

[144] L. Zhu, P. Gibson, D. S. Currle, et al., “Prominin1 Marks Intestinal Stem Cells That Are Susceptible to Neoplastic Transformation,” Nature 457, no. 7229 (2009): 603–607.

[145] S. Takaishi, T. Okumura, S. Tu, et al., “Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker Cd44,” Stem Cells 27, no. 5 (2009): 1006–1020.

[146] H. H. Lee, K. J. Seo, C. H. An, J. S. Kim, and H. M. Jeon, “CD133 Expression Is Correlated With Chemoresistance and Early Recurrence of Gastric Cancer,” Journal of Surgical Oncology 106, no. 8 (2012): 999–1004.

[147] P. Gupta, S. Z. Rizvi, N. Lal, V. Gupta, A. N. Srivastav, and O. Musa, “Expression of CD44 and CD133 Stem Cell Markers in Squamous Cell Carcinoma of Esophagus,” Indian Journal of Pathology and Microbiology 64, no. 3 (2021): 472–478.

[148] C. Lu, F. Xu, J. Gu, et al., “Clinical and Biological Significance of Stem-Like CD133⁺CXCR4⁺ Cells in Esophageal Squamous Cell Carcinoma,” Journal of Thoracic and Cardiovascular Surgery 150, no. 2 (2015): 386–395.

[149] H. J. Lee, D. D. You, D. W. Choi, et al., “Significance of CD133 as a Cancer Stem Cell Markers Focusing on the Tumorigenicity of Pancreatic Cancer Cell Lines,” Journal of the Korean Surgical Society 81, no. 4 (2011): 263–270.

[150] X. Ding, J. Wu, and C. Jiang, “ABCG2: A Potential Marker of Stem Cells and Novel Target in Stem Cell and Cancer Therapy,” Life Sciences 86, no. 17 (2010): 631–637.

[151] F. Wei, T. Zhang, S.-C. Deng, et al., “PD-L1 Promotes Colorectal Cancer Stem Cell Expansion by Activating HMGA1-Dependent Signaling Pathways,” Cancer Letters 450 (2019): 1–13.

[152] G.-L. Xu, C.-F. Ni, H.-S. Liang, et al., “Upregulation of PD-L1 Expression Promotes Epithelial-to-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells,” Gastroenterology Report 8, no. 5 (2020): 390–398.

[153] L. Sun, C. Huang, M. Zhu, et al., “Gastric Cancer Mesenchymal Stem Cells Regulate PD-L1-CTCF Enhancing Cancer Stem Cell-Like Properties and Tumorigenesis,” Theranostics 10, no. 26 (2020): 11950–11962.

[154] W. Zhao, L. Wang, H. Han, et al., “1B50-1, a mAb Raised against Recurrent Tumor Cells, Targets Liver Tumor-Initiating Cells by Binding to the Calcium Channel Α2δ1 Subunit,” Cancer Cell 23, no. 4 (2013): 541–556.

[155] R. K. Montgomery and R. A. Shivdasani, “Prominin1 (CD133) as an Intestinal Stem Cell Marker: Promise and Nuance,” Gastroenterology 136, no. 7 (2009): 2051–2054.

[156] M. R. Atashzar, R. Baharlou, J. Karami, et al., “Cancer Stem Cells: A Review From Origin to Therapeutic Implications,” Journal of Cellular Physiology 235, no. 2 (2020): 790–803.

[157] G. Driessens, B. Beck, A. Caauwe, B. D. Simons, and C. Blanpain, “Defining the Mode of Tumour Growth by Clonal Analysis,” Nature 488, no. 7412 (2012): 527–530.

[158] Y. Nakanishi, H. Seno, A. Fukuoka, et al., “Dclk1 Distinguishes Between Tumor and Normal Stem Cells in the Intestine,” Nature Genetics 45, no. 1 (2013): 98–103.

[159] T. Sato, D. E. Stange, M. Ferrante, et al., “Long-Term Expansion of Epithelial Organoids From Human Colon, Adenoma, Adenocarcinoma, and Barrett's Epithelium,” Gastroenterology 141, no. 5 (2011): 1762–1772.

[160] Z. Wang, Q. Wang, C. Chen, et al., “NNMT Enriches for AQP5⁺ Cancer Stem Cells to Drive Malignant Progression in Early Gastric Cardia Adenocarcinoma,” Gut 73, no. 1 (2023): 63–77.

[161] N. K. Lytle, L. P. Ferguson, N. Rajbhandari, et al., “A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma,” Cell 177, no. 3 (2019): 572–586.

[162] B. L. LeSavage, R. A. Suhar, N. Broguiere, M. P. Lutolf, and S. C. Heilshorn, “Next-Generation Cancer Organoids,” Nature Materials 21, no. 2 (2022): 143–159.

[163] N. S. Corsini and J. A. Knoblich, “Human Organoids: New Strategies and Methods for Analyzing Human Development and Disease,” Cell 185, no. 15 (2022): 2756–2769.

[164] M. Hofer and M. P. Lutolf, “Engineering Organoids,” Nature Reviews Materials 6, no. 5 (2021): 402–420.

[165] T. M. Malta, A. Sokolov, A. J. Gentles, et al., “Machine Learning Identifies Stemness Features Associated With Oncogenic Dedifferentiation,” Cell 173, no. 2 (2018): 338–354.

[166] S. Yuan, K. S. Stewart, Y. Yang, et al., “Ras Drives Malignancy Through Stem Cell Crosstalk With the Microenvironment,” Nature 612, no. 7940 (2022): 555–563.

[167] B. Chen, C. R. Scurrah, E. T. McKinley, et al., “Differential Pre-Malignant Programs and Microenvironment Chart Distinct Paths to Malignancy in Human Colorectal Polyps,” Cell 184, no. 26 (2021): 6262–6280.

[168] L. Zhou, R. Wen, C. Bai, et al., “Spatial Transcriptomic Revealed Intratumor Heterogeneity and Cancer Stem Cell Enrichment in Colorectal Cancer Metastasis,” Cancer Letters 602 (2024): 217181.

[169] G. La Manno, R. Soldatov, A. Zeisel, et al., “RNA Velocity of Single Cells,” Nature 560, no. 7719 (2018): 494–498.

[170] G. S. Gulati, S. S. Sikandar, D. J. Wesche, et al., “Single-Cell Transcriptional Diversity Is a Hallmark of Developmental Potential,” Science 367, no. 6476 (2020): 405–411.

[171] S. Jin, C. F. Guerrero-Juarez, L. Zhang, et al., “Inference and Analysis of Cell–Cell Communication Using CellChat,” Nature Communications 12, no. 1 (2021): 1088.

[172] M. Efremova, M. Vento-Tormo, S. A. Teichmann, and R. Vento-Tormo, “CellPhoneDB: Inferring Cell–Cell Communication From Combined Expression of Multi-Subunit Ligand-Receptor Complexes,” Nature Protocols 15, no. 4 (2020): 1484–1506.

[173] D. J. Flanagan, N. Pentinmikko, K. Luopajärvi, et al., “NOTUM From Apc-Mutant Cells Biases Clonal Competition to Initiate Cancer,” Nature 594, no. 7863 (2021): 430–435.

[174] S. M. van Neerven, N. E. de Groot, L. E. Nijman, et al., “Apc-Mutant Cells Act as Supercompetitors in Intestinal Tumour Initiation,” Nature 594, no. 7863 (2021): 436–441.

[175] M. K. Yum, S. Han, J. Fink, et al., “Tracing Oncogene-Driven Remodelling of the Intestinal Stem Cell Niche,” Nature 594, no. 7863 (2021): 442–447.

[176] Z. Chen, L. He, L. Zhao, et al., “circREEP3 Drives Colorectal Cancer Progression via Activation of FKBP10 Transcription and Restriction of Antitumor Immunity,” Advanced Science 9, no. 13 (2022): e2105160.

[177] S. M. Man, Q. Zhu, L. Zhu, et al., “Critical Role for the DNA Sensor AIM2 in Stem Cell Proliferation and Cancer,” Cell 162, no. 1 (2015): 45–58.

[178] T. Yu, F. Guo, Y. Yu, et al., “Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy,” Cell 170, no. 3 (2017): 548–563.

[179] X. Zhi, L. Lin, S. Yang, et al., “βII-Spectrin (SPTBN1) Suppresses Progression of Hepatocellular Carcinoma and Wnt Signaling by Regulation of Wnt Inhibitor Kallistatin,” Hepatology 61, no. 2 (2015): 598–612.

[180] K. K. Y. Lai, S.-M. Kweon, F. Chi, et al., “Stearoyl-CoA Desaturase Promotes Liver Fibrosis and Tumor Development in Mice via a Wnt Positive-Signaling Loop by Stabilization of Low-Density Lipoprotein-Receptor-Related Proteins 5 and 6,” Gastroenterology 152, no. 6 (2017): 1477–1491.

[181] H.-H. Chua, D.-J. Tsuei, P.-H. Lee, et al., “RBMY, a Novel Inhibitor of Glycogen Synthase Kinase 3β, Increases Tumor Stemness and Predicts Poor Prognosis of Hepatocellular Carcinoma,” Hepatology 62, no. 5 (2015): 1480–1496.

[182] Z.-F. Miao, H. Xu, H.-M. Xu, et al., “DLL4 Overexpression Increases Gastric Cancer Stem/Progenitor Cell Self-Renewal Ability and Correlates With Poor Clinical Outcome via Notch-1 Signaling Pathway Activation,” Cancer Medicine 6, no. 1 (2017): 245–257.

[183] C. Zeng, Y. Wang, Q. Lu, et al., “SPOP Suppresses Tumorigenesis by Regulating Hedgehog/Gli2 Signaling Pathway in Gastric Cancer,” Journal of Experimental & Clinical Cancer Research 33, no. 1 (2014): 75.

[184] P. Zhu, Y. Wang, L. He, et al., “ZIC2-Dependent OCT4 Activation Drives Self-Renewal of Human Liver Cancer Stem Cells,” Journal of Clinical Investigation 125, no. 10 (2015): 3795–3808.

[185] H. Han, Y. Du, W. Zhao, et al., “PBX3 Is Targeted by Multiple miRNAs and Is Essential for Liver Tumour-Initiating Cells,” Nature Communications 6 (2015): 8271.

[186] C. Liu, L. Liu, X. Chen, et al., “Sox9 Regulates Self-Renewal and Tumorigenicity by Promoting Symmetrical Cell Division of Cancer Stem Cells in Hepatocellular Carcinoma,” Hepatology 64, no. 1 (2016): 117–129.

[187] P. Zhu, Y. Wang, Y. Du, et al., “C8orf4 Negatively Regulates Self-Renewal of Liver Cancer Stem Cells via Suppression of NOTCH2 Signalling,” Nature Communications 6 (2015): 7122.

[188] S. S. Zeng, T. Yamashita, M. Kondo, et al., “The Transcription Factor SALL4 Regulates Stemness of EpCAM-Positive Hepatocellular Carcinoma,” Journal of Hepatology 60, no. 1 (2014): 127–134.

[189] D. Kopanja, A. Pandey, M. Kiefer, et al., “Essential Roles of FoxM1 in Ras-Induced Liver Cancer Progression and in Cancer Cells With Stem Cell Features,” Journal of Hepatology 63, no. 2 (2015): 429–436.

[190] P. Ordóñez-Morán, C. Dafflon, M. Imajo, E. Nishida, and J. Huelsken, “HOXA5 Counteracts Stem Cell Traits by Inhibiting Wnt Signaling in Colorectal Cancer,” Cancer Cell 28, no. 6 (2015): 815–829.

[191] Q. Wang, N. Liang, T. Yang, et al., “DNMT1-Mediated Methylation of BEX1 Regulates Stemness and Tumorigenicity in Liver Cancer,” Journal of Hepatology 75, no. 5 (2021): 1142–1153.

[192] H. You, W. Ding, and B. C. Rountree, “Epigenetic Regulation of Cancer Stem Cell Marker Cd133 by Transforming Growth Factor-β,” Hepatology 51, no. 5 (2010): 1635–1644.

[193] C. Raggi, V. M. Factor, D. Seo, et al., “Epigenetic Reprogramming Modulates Malignant Properties of Human Liver Cancer,” Hepatology 59, no. 6 (2014): 2251–2262.

[194] Z.-J. Lei, J. Wang, H.-L. Xiao, et al., “Lysine-Specific Demethylase 1 Promotes the Stemness and Chemoresistance of LGR5⁺ Liver Cancer Initiating Cells by Suppressing Negative Regulators of β-Catenin Signaling,” Oncogene 34, no. 24 (2015): 3188–3198.

[195] J. Grinat, J. Heuberger, R. O. Vidal, et al., “The Epigenetic Regulator Mll1 Is Required for Wnt-Driven Intestinal Tumorigenesis and Cancer Stemness,” Nature Communications 11, no. 1 (2020): 6422.

[196] X. Wang, J. Wang, Y.-M. Tsui, et al., “RALYL Increases Hepatocellular Carcinoma Stemness by Sustaining the mRNA Stability of TGF-Β2,” Nature Communications 12, no. 1 (2021): 1518.

[197] Y. Wang, J. Wang, X. Li, et al., “N1-Methyladenosine Methylation in tRNA Drives Liver Tumourigenesis by Regulating Cholesterol Metabolism,” Nature Communications 12, no. 1 (2021): 6314.

[198] S. Ma, K. H. Tang, Y. P. Chan, et al., “miR-130b Promotes CD133⁺ Liver Tumor-Initiating Cell Growth and Self-Renewal via Tumor Protein 53-Induced Nuclear Protein 1,” Cell Stem Cell 7, no. 6 (2010): 694–707.

[199] L. Li, Y. Liu, Y. Guo, et al., “Regulatory MiR-148a-ACVR1/BMP Circuit Defines a Cancer Stem Cell-Like Aggressive Subtype of Hepatocellular Carcinoma,” Hepatology 61, no. 2 (2015): 574–584.

[200] Y. Gu, X. Wei, Y. Sun, et al., “miR-192-5p Silencing by Genetic Aberrations Is a Key Event in Hepatocellular Carcinomas With Cancer Stem Cell Features,” Cancer Research 79, no. 5 (2019): 941–953.

[201] L. Li, J. Tang, B. Zhang, et al., “Epigenetic Modification of MiR-429 Promotes Liver Tumour-Initiating Cell Properties by Targeting Rb Binding Protein 4,” Gut 64, no. 1 (2015): 156–167.

[202] P. Zhu, Y. Wang, J. Wu, et al., “LncBRM Initiates YAP1 Signalling Activation to Drive Self-Renewal of Liver Cancer Stem Cells,” Nature Communications 7 (2016): 13608.

[203] P. Zhu, Y. Wang, G. Huang, et al., “Lnc-β-Catm Elicits EZH2-Dependent β-Catenin Stabilization and Sustains Liver CSC Self-Renewal,” Nature Structural & Molecular Biology 23 (2016): 631–639.

[204] S. Yuan, J. Wang, F. Yang, et al., “Long Noncoding RNA DANCR Increases Stemness Features of Hepatocellular Carcinoma by Derepression of CTNNB1,” Hepatology 63, no. 2 (2016): 499–511.

[205] F. Wang, J.-H. Yuan, S.-B. Wang, et al., “Oncofetal Long Noncoding RNA PVT1 Promotes Proliferation and Stem Cell-Like Property of Hepatocellular Carcinoma Cells by Stabilizing NOP2,” Hepatology 60, no. 4 (2014): 1278–1290.

[206] Y. Gu, Y. Wang, L. He, et al., “Circular RNA circIPO11 Drives Self-Renewal of Liver Cancer Initiating Cells via Hedgehog Signaling,” Molecular Cancer 20, no. 1 (2021): 132.

[207] L. Yang, P. Shi, G. Zhao, et al., “Targeting Cancer Stem Cell Pathways for Cancer Therapy,” Signal Transduction and Targeted Therapy 5, no. 1 (2020): 8.

[208] M. Kahn, “Can We Safely Target the WNT Pathway?,” Nature Reviews Drug Discovery 13, no. 7 (2014): 513–532.

[209] H. F. Farin, I. Jordens, M. H. Mosa, et al., “Visualization of a Short-Range Wnt Gradient in the Intestinal Stem-Cell Niche,” Nature 530, no. 7590 (2016): 340–343.

[210] M. Katoh, “Canonical and Non-Canonical WNT Signaling in Cancer Stem Cells and Their Niches: Cellular Heterogeneity, Omics Reprogramming, Targeted Therapy and Tumor Plasticity (Review),” International Journal of Oncology 51, no. 5 (2017): 1357–1369.

[211] T. Pan, J. Xu, and Y. Zhu, “Self-Renewal Molecular Mechanisms of Colorectal Cancer Stem Cells,” International Journal of Molecular Medicine 39, no. 1 (2017): 9–20.

[212] S. Mokkapati, K. Niopek, L. Huang, et al., “β-Catenin Activation in a Novel Liver Progenitor Cell Type Is Sufficient to Cause Hepatocellular Carcinoma and Hepatoblastoma,” Cancer Research 74, no. 16 (2014): 4515–4525.

[213] A. B. Sparks, P. J. Morin, B. Vogelstein, and K. W. Kinzler, “Mutational Analysis of the APC/Beta-Catenin/Tcf Pathway in Colorectal Cancer,” Cancer Research 58, no. 6 (1998): 1130–1134.

[214] P. Laurent–Puig, P. Legoix, O. Bluteau, et al., “Genetic Alterations Associated With Hepatocellular Carcinomas Define Distinct Pathways of Hepatocarcinogenesis,” Gastroenterology 120, no. 7 (2001): 1763–1773.

[215] W. M. Clements, J. Wang, A. Sarnaik, et al., “Beta-Catenin Mutation Is a Frequent Cause of Wnt Pathway Activation in Gastric Cancer,” Cancer Research 62, no. 12 (2002): 3503–3506.

[216] S. M. Mazzoni and E. R. Fearon, “AXIN1 and AXIN2 Variants in Gastrointestinal Cancers,” Cancer Letters 355, no. 1 (2014): 1–8.

[217] Z. Chen, Y. Gao, L. Yao, et al., “LncFZD6 Initiates Wnt/β-Catenin and Liver TIC Self-Renewal Through BRG1-Mediated FZD6 Transcriptional Activation,” Oncogene 37, no. 23 (2018): 3098–3112.

[218] P. Zhu, J. Wu, Y. Wang, et al., “LncGata6 Maintains Stemness of Intestinal Stem Cells and Promotes Intestinal Tumorigenesis,” Nature Cell Biology 20, no. 10 (2018): 1134–1144.

[219] P. Zhu, X. Zhu, J. Wu, et al., “IL-13 Secreted by ILC2s Promotes the Self-Renewal of Intestinal Stem Cells Through Circular RNA CircPan3,” Nature Immunology 20, no. 2 (2019): 183–194.

[220] P. Zhu, T. Lu, J. Wu, et al., “Gut Microbiota Drives Macrophage-Dependent Self-Renewal of Intestinal Stem Cells via Niche Enteric Serotonergic Neurons,” Cell Research 32, no. 6 (2022): 555–569.

[221] L. Vermeulen, F. De Sousa, E. Melo, M. van der Heijden, et al., “Wnt Activity Defines Colon Cancer Stem Cells and Is Regulated by the Microenvironment,” Nature Cell Biology 12, no. 5 (2010): 468–476.

[222] N. Sachan, V. Sharma, M. Mutsuddi, and A. Mukherjee, “Notch Signalling: Multifaceted Role in Development and Disease,” FEBS Journal 291, no. 14 (2024): 3030–3059.

[223] S. Zhang, H. Zhao, Z. Liu, et al., “Monitoring of Cell-Cell Communication and Contact History in Mammals,” Science 378, no. 6623 (2022): eabo5503.

[224] E. H. Schroeter, J. A. Kisslinger, and R. Kopan, “Notch-1 Signalling Requires Ligand-Induced Proteolytic Release of Intracellular Domain,” Nature 393, no. 6683 (1998): 382–386.

[225] W. Zhou, X.-Q. Fu, L.-L. Zhang, et al., “The AKT1/NF-kappaB/Notch1/PTEN Axis Has an Important Role in Chemoresistance of Gastric Cancer Cells,” Cell Death & Disease 4, no. 10 (2013): e847.

[226] Y. Zhang, B. Li, Z.-Z. Ji, and P.-S. Zheng, “Notch1 Regulates the Growth of Human Colon Cancers,” Cancer 116, no. 22 (2010): 5207–5218.

[227] P. Viatour, U. Ehmer, L. A. Saddic, et al., “Notch Signaling Inhibits Hepatocellular Carcinoma Following Inactivation of the RB Pathway,” Journal of Experimental Medicine 208, no. 10 (2011): 1963–1976.

[228] F. Zhang, H. Sun, S. Zhang, X. Yang, G. Zhang, and T. Su, “Overexpression of PER3 Inhibits Self-Renewal Capability and Chemoresistance of Colorectal Cancer Stem-Like Cells via Inhibition of Notch and β-Catenin Signaling,” Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 25, no. 5 (2017): 709–719.

[229] H. Gehart and H. Clevers, “Tales From the Crypt: New Insights into Intestinal Stem Cells,” Nature Reviews Gastroenterology & Hepatology 16, no. 1 (2019): 19–34.

[230] J. Briscoe and P. P. Thérond, “The Mechanisms of Hedgehog Signalling and Its Roles in Development and Disease,” Nature Reviews Molecular Cell Biology 14, no. 7 (2013): 416–429.

[231] C. Yoon, D. J. Park, B. Schmidt, et al., “RETRACTED: CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance,” Clinical Cancer Research 20, no. 15 (2014): 3974–3988.

[232] Z. Song, W. Yue, B. Wei, et al., “Sonic Hedgehog Pathway Is Essential for Maintenance of Cancer Stem-Like Cells in Human Gastric Cancer,” PLoS One 6, no. 3 (2011): e17687.

[233] Y. Kong, Y. Peng, Y. Liu, H. Xin, X. Zhan, and W. Tan, “Twist1 and Snail Link Hedgehog Signaling to Tumor-Initiating Cell-Like Properties and Acquired Chemoresistance Independently of ABC Transporters,” Stem Cells 33, no. 4 (2015): 1063–1074.

[234] R. McMillan and W. Matsui, “Molecular Pathways: The Hedgehog Signaling Pathway in Cancer,” Clinical Cancer Research 18, no. 18 (2012): 4883–4888.

[235] Y. Xu, Y. An, X. Wang, W. Zha, and X. Li, “Inhibition of the Hedgehog Pathway Induces Autophagy in Pancreatic Ductal Adenocarcinoma Cells,” Oncology Reports 31, no. 2 (2014): 707–712.

[236] J. Wu, P. Zhu, T. Lu, et al., “The Long Non-Coding RNA LncHDAC2 Drives the Self-Renewal of Liver Cancer Stem Cells via Activation of Hedgehog Signaling,” Journal of Hepatology 70, no. 5 (2019): 918–929.

[237] S. Schön, I. Flierman, A. Ofner, et al., “β-Catenin Regulates NF-κB Activity via TNFRSF19 in Colorectal Cancer Cells,” International Journal of Cancer 135, no. 8 (2014): 1800–1811.

[238] D. Liu, L. Du, D. Chen, et al., “Reduced CD146 Expression Promotes Tumorigenesis and Cancer Stemness in Colorectal Cancer Through Activating Wnt/β-Catenin Signaling,” Oncotarget 7, no. 26 (2016): 40704–40718.

[239] Q. Du, X. Zhang, J. Cardinal, et al., “Wnt/β-Catenin Signaling Regulates Cytokine-Induced Human Inducible Nitric Oxide Synthase Expression by Inhibiting Nuclear Factor-κB Activation in Cancer Cells,” Cancer Research 69, no. 9 (2009): 3764–3771.

[240] G. Thyssen, T.-H. Li, L. Lehmann, M. Zhuo, M. Sharma, and Z. Sun, “LZTS2 Is a Novel β-Catenin-Interacting Protein and Regulates the Nuclear Export of β-Catenin,” Molecular and Cellular Biology 26, no. 23 (2006): 8857–8867.

[241] F. K. Noubissi, S. Goswami, N. A. Sanek, et al., “Wnt Signaling Stimulates Transcriptional Outcome of the Hedgehog Pathway by Stabilizing GLI1 mRNA,” Cancer Research 69, no. 22 (2009): 8572–8578.

[242] J. L. Regan, D. Schumacher, S. Staudte, et al., “Non-Canonical Hedgehog Signaling Is a Positive Regulator of the WNT Pathway and Is Required for the Survival of Colon Cancer Stem Cells,” Cell Reports 21, no. 10 (2017): 2813–2828.

[243] M. Zuo, A. Rashid, C. Churi, et al., “Novel Therapeutic Strategy Targeting the Hedgehog Signalling and mTOR Pathways in Biliary Tract Cancer,” British Journal of Cancer 112, no. 6 (2015): 1042–1051.

[244] X. Zhu, H.-H. Chen, C.-Y. Gao, et al., “Energy Metabolism in Cancer Stem Cells,” World Journal of Stem Cells 12, no. 6 (2020): 448–461.

[245] H. Liu, Z. Zhang, L. Song, J. Gao, and Y. Liu, “Lipid Metabolism of Cancer Stem Cells,” Oncology Letters 23, no. 4 (2022): 119.

[246] S. Recalcati, E. Gammella, and G. Cairo, “Dysregulation of Iron Metabolism in Cancer Stem Cells,” Free Radical Biology and Medicine 133 (2019): 216–220.

[247] S. Ghosh, S. K. Juin, and S. Majumdar, “Cancer Stem Cells and Ceramide Signaling: The Cutting Edges of Immunotherapy,” Molecular Biology Reports 47, no. 10 (2020): 8101–8111.

[248] M. V. Liberti and J. W. Locasale, “The Warburg Effect: How Does It Benefit Cancer Cells?,” Trends in Biochemical Sciences 41, no. 3 (2016): 211–218.

[249] C. L. Jones, A. Inguva, and C. T. Jordan, “Targeting Energy Metabolism in Cancer Stem Cells: Progress and Challenges in Leukemia and Solid Tumors,” Cell Stem Cell 28, no. 3 (2021): 378–393.

[250] Z. Wei, J. Jia, G. Heng, et al., “Sirtuin-1/Mitochondrial Ribosomal Protein S5 Axis Enhances the Metabolic Flexibility of Liver Cancer Stem Cells,” Hepatology 70, no. 4 (2019): 1197–1213.

[251] C.-L. Chen, D. B. Uthaya Kumar, V. Punj, et al., “NANOG Metabolically Reprograms Tumor-Initiating Stem-Like Cells Through Tumorigenic Changes in Oxidative Phosphorylation and Fatty Acid Metabolism,” Cell Metabolism 23, no. 1 (2016): 206–219.

[252] K. Fekir, H. Dubois-Pot-Schneider, R. Désert, et al., “Retrodifferentiation of Human Tumor Hepatocytes to Stem Cells Leads to Metabolic Reprogramming and Chemoresistance,” Cancer Research 79, no. 8 (2019): 1869–1883.

[253] S. Valle, S. Alcalá, L. Martin-Hijano, et al., “Exploiting Oxidative Phosphorylation to Promote the Stem and Immunoevasive Properties of Pancreatic Cancer Stem Cells,” Nature Communications 11, no. 1 (2020): 5265.

[254] C. Raggi, M. L. Taddei, E. Sacco, et al., “Mitochondrial Oxidative Metabolism Contributes to a Cancer Stem Cell Phenotype in Cholangiocarcinoma,” Journal of Hepatology 74, no. 6 (2021): 1373–1385.

[255] C. L. Jones, B. M. Stevens, A. D'Alessandro, et al., “Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells,” Cancer Cell 34, no. 5 (2018): 724–740.

[256] C. C. Wong, J. Xu, X. Bian, et al., “In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance,” Gastroenterology 159, no. 6 (2020): 2163–2180.

[257] J. Vande Voorde, R. T. Steven, A. K. Najumudeen, et al., “Metabolic Profiling Stratifies Colorectal Cancer and Reveals Adenosylhomocysteinase as a Therapeutic Target,” Nature Metabolism 5, no. 8 (2023): 1303–1318.

[258] Q. Sun, Z. Zhang, Y. Lu, et al., “Loss of Xanthine Oxidoreductase Potentiates Propagation of Hepatocellular Carcinoma Stem Cells,” Hepatology 71, no. 6 (2020): 2033–2049.

[259] A. Budhu, S. Roessler, X. Zhao, et al., “Integrated Metabolite and Gene Expression Profiles Identify Lipid Biomarkers Associated With Progression of Hepatocellular Carcinoma and Patient Outcomes,” Gastroenterology 144, no. 5 (2013): 1066–1075.

[260] M. K. F. Ma, E. Y. T. Lau, D. H. W. Leung, et al., “Stearoyl-CoA Desaturase Regulates Sorafenib Resistance via Modulation of ER Stress-Induced Differentiation,” Journal of Hepatology 67, no. 5 (2017): 979–990.

[261] S. Beyaz, M. D. Mana, J. Roper, et al., “High-Fat Diet Enhances Stemness and Tumorigenicity of Intestinal Progenitors,” Nature 531, no. 7592 (2016): 53–58.

[262] K. Takahashi and S. Yamanaka, “Induction of Pluripotent Stem Cells From Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors,” Cell 126, no. 4 (2006): 663–676.

[263] H. Fatma and H. R. Siddique, “Pluripotency Inducing Yamanaka Factors: Role in Stemness and Chemoresistance of Liver Cancer,” Expert Review of Anticancer Therapy 21, no. 8 (2021): 853–864.

[264] S. Galardi, M. Savino, F. Scagnoli, et al., “Resetting Cancer Stem Cell Regulatory Nodes Upon MYC Inhibition,” EMBO Reports 17, no. 12 (2016): 1872–1889.

[265] C. M. Shachaf, A. M. Kopelman, C. Arvanitis, et al., “MYC Inactivation Uncovers Pluripotent Differentiation and Tumour Dormancy in Hepatocellular Cancer,” Nature 431, no. 7012 (2004): 1112–1117.

[266] X.-Y. Qin, H. Suzuki, M. Honda, et al., “Prevention of Hepatocellular Carcinoma by Targeting MYCN-Positive Liver Cancer Stem Cells With Acyclic Retinoid,” Proceedings of the National Academy of Sciences 115, no. 19 (2018): 4969–4974.

[267] S. D. Conzen, K. Gottlob, E. S. Kandel, et al., “Induction of Cell Cycle Progression and Acceleration of Apoptosis Are Two Separable Functions of C-Myc: Transrepression Correlates With Acceleration of Apoptosis,” Molecular and Cellular Biology 20, no. 16 (2000): 6008–6018.

[268] X. Q. Wang, R. K. Ng, X. Ming, et al., “Epigenetic Regulation of Pluripotent Genes Mediates Stem Cell Features in Human Hepatocellular Carcinoma and Cancer Cell Lines,” PLoS One 8, no. 9 (2013): e72435.

[269] T. Lin, Y.-Q. Ding, and J.-M. Li, “Overexpression of Nanog Protein Is Associated With Poor Prognosis in Gastric Adenocarcinoma,” Medical Oncology 29, no. 2 (2012): 878–885.

[270] Y. Lu, H. Zhu, H. Shan, et al., “Knockdown of Oct4 and Nanog Expression Inhibits the Stemness of Pancreatic Cancer Cells,” Cancer Letters 340, no. 1 (2013): 113–123.

[271] M. Flandez, S. Guilmeau, P. Blache, and L. H. Augenlicht, “KLF4 Regulation in Intestinal Epithelial Cell Maturation,” Experimental Cell Research 314, no. 20 (2008): 3712–3723.

[272] Y. G. Cho, J. H. Song, C. J. Kim, et al., “Genetic and Epigenetic Analysis of the KLF4 Gene in Gastric Cancer,” APMIS 115, no. 7 (2007): 802–808.

[273] Q. Li, Y. Gao, Z. Jia, et al., “Dysregulated Krüppel-Like Factor 4 and Vitamin D Receptor Signaling Contribute to Progression of Hepatocellular Carcinoma,” Gastroenterology 143, no. 3 (2012): 799–810.

[274] A. Luo, J. Kong, G. Hu, et al., “Discovery of Ca2⁺-Relevant and Differentiation-Associated Genes Downregulated in Esophageal Squamous Cell Carcinoma Using cDNA Microarray,” Oncogene 23, no. 6 (2004): 1291–1299.

[275] H. Fan, Z. Cui, H. Zhang, et al., “DNA Demethylation Induces SALL4 Gene Re-Expression in Subgroups of Hepatocellular Carcinoma Associated With Hepatitis B or C Virus Infection,” Oncogene 36, no. 17 (2017): 2435–2445.

[276] X. Liu, B. Chen, F. Xie, et al., “FOXP4 Is a Direct YAP1 Target That Promotes Gastric Cancer Stemness and Drives Metastasis,” Cancer Research 84, no. 21 (2024): 3574–3588.

[277] L. Cao, K. Weng, L. Li, et al., “BATF2 Inhibits the Stem Cell-Like Properties and Chemoresistance of Gastric Cancer Cells Through PTEN/AKT/β-Catenin Pathway,” Theranostics 14, no. 18 (2024): 7007–7022.

[278] L. H. Chan, L. Zhou, K. Y. Ng, et al., “PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma Through CRAF Methylation,” Cell Reports 25, no. 3 (2018): 690–701.

[279] L. Liu, C. Liu, Q. Zhang, et al., “SIRT1-Mediated Transcriptional Regulation of SOX2 Is Important for Self-Renewal of Liver Cancer Stem Cells,” Hepatology 64, no. 3 (2016): 814–827.

[280] O. Lo Re, C. Fusilli, F. Rappa, et al., “Induction of Cancer Cell Stemness by Depletion of Macrohistone H2A1 in Hepatocellular Carcinoma,” Hepatology 67, no. 2 (2018): 636–650.

[281] T. Chiba, S. Miyagi, A. Saraya, et al., “The Polycomb Gene Product BMI1 Contributes to the Maintenance of Tumor-Initiating Side Population Cells in Hepatocellular Carcinoma,” Cancer Research 68, no. 19 (2008): 7742–7749.

[282] Z. Chen, Y. He, L. Zhang, and Y. Li, “Enhanced DNA Release From Disulfide-Containing Layered Nanocomplexes by Heparin-Electrostatic Competition,” Journal of Materials Chemistry B 3, no. 2 (2015): 225–237.

[283] Y. Feng, L. Cai, M. Pook, et al., “BRD9-SMAD2/3 Orchestrates Stemness and Tumorigenesis in Pancreatic Ductal Adenocarcinoma,” Gastroenterology 166, no. 1 (2024): 139–154.

[284] X. Wang, B. S. Zhao, I. A. Roundtree, et al., “N(6)-Methyladenosine Modulates Messenger RNA Translation Efficiency,” Cell 161, no. 6 (2015): 1388–1399.

[285] X. Wang, Z. Lu, A. Gomez, et al., “N6-Methyladenosine-Dependent Regulation of Messenger RNA Stability,” Nature 505, no. 7481 (2014): 117–120.

[286] J. Liu, X. Dou, C. Chen, et al., “N6-Methyladenosine of Chromosome-Associated Regulatory RNA Regulates Chromatin State and Transcription,” Science 367, no. 6477 (2020): 580–586.

[287] C. Zhang, S. Huang, H. Zhuang, et al., “YTHDF2 Promotes the Liver Cancer Stem Cell Phenotype and Cancer Metastasis by Regulating OCT4 Expression via m6A RNA Methylation,” Oncogene 39, no. 23 (2020): 4507–4518.

[288] J. Luo, L. Gong, Y. Yang, et al., “Enhanced Mitophagy Driven by ADAR1-GLI1 Editing Supports the Self-Renewal of Cancer Stem Cells in HCC,” Hepatology 79, no. 1 (2024): 61–78.

[289] P. Zhu, B. Liu, and Z. Fan, “Noncoding RNAs in Tumorigenesis and Tumor Therapy,” Fundamental Research 3, no. 5 (2023): 692–706.

[290] S. Chai, K.-Y. Ng, M. Tong, et al., “Octamer 4/microRNA-1246 Signaling Axis Drives Wnt/β-Catenin Activation in Liver Cancer Stem Cells,” Hepatology 64, no. 6 (2016): 2062–2076.

[291] Z. Chen, L. Huang, Y. Wu, W. Zhai, P. Zhu, and Y. Gao, “LncSox4 Promotes the Self-Renewal of Liver Tumour-Initiating Cells Through Stat3-Mediated Sox4 Expression,” Nature Communications 7 (2016): 12598.

[292] L. Chen, R. Kong, C. Wu, et al., “Circ-MALAT1 Functions as Both an mRNA Translation Brake and a microRNA Sponge to Promote Self-Renewal of Hepatocellular Cancer Stem Cells,” Advanced Science 7, no. 4 (2020): 1900949.

[293] Y.-Y. Tseng, B. S. Moriarity, W. Gong, et al., “PVT1 Dependence in Cancer With MYC Copy-Number Increase,” Nature 512, no. 7512 (2014): 82–86.

[294] V. Plaks, N. Kong, and Z. Werb, “The Cancer Stem Cell Niche: How Essential Is the Niche in Regulating Stemness of Tumor Cells?,” Cell Stem Cell 16, no. 3 (2015): 225–238.

[295] K. E. de Visser and J. A. Joyce, “The Evolving Tumor Microenvironment: From Cancer Initiation to Metastatic Outgrowth,” Cancer Cell 41, no. 3 (2023): 374–403.

[296] K. H. Tang, S. Ma, T. K. Lee, et al., “CD133⁺ Liver Tumor-Initiating Cells Promote Tumor Angiogenesis, Growth, and Self-Renewal Through Neurotensin/Interleukin-8/CXCL1 Signaling,” Hepatology 55, no. 3 (2012): 807–820.

[297] Q.-Z. Pan, K. Pan, D.-S. Weng, et al., “Annexin A3 Promotes Tumorigenesis and Resistance to Chemotherapy in Hepatocellular Carcinoma,” Molecular Carcinogenesis 54, no. 8 (2015): 598–607.

[298] M. Tong, T.-M. Fung, S. T. Luk, et al., “ANXA3/JNK Signaling Promotes Self-Renewal and Tumor Growth, and Its Blockade Provides a Therapeutic Target for Hepatocellular Carcinoma,” Stem Cell Reports 5, no. 1 (2015): 45–59.

[299] M. Tong, N. Che, L. Zhou, et al., “Efficacy of Annexin A3 Blockade in Sensitizing Hepatocellular Carcinoma to Sorafenib and Regorafenib,” Journal of Hepatology 69, no. 4 (2018): 826–839.

[300] E. Dong, X. Yue, L. Shui, et al., “IFN-γ Surmounts PD-L1/PD1 Inhibition to CAR-T Cell Therapy by Upregulating ICAM-1 on Tumor Cells,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 20.

[301] S. Kakugawa, P. F. Langton, M. Zebisch, et al., “Notum Deacylates Wnt Proteins to Suppress Signalling Activity,” Nature 519, no. 7542 (2015): 187–192.

[302] T. Hillen and A. Shyntar, “ Modelling of Cancer Stem Cell Driven Solid Tumors.” in Problems in Mathematical Biophysics: A Volume in Memory of Alberto Gandolfi, ed. A. d'Onofrio, A. Fasano, F. Papa, and C. Sinisgalli (Springer Nature, 2024), 129–155.

[303] T. Sato, J. H. van Es, H. J. Snippert, et al., “Paneth Cells Constitute the Niche for LGR5 Stem Cells in Intestinal Crypts,” Nature 469, no. 7330 (2011): 415–418.

[304] M. J. Rodríguez-Colman, M. Schewe, M. Meerlo, et al., “Interplay Between Metabolic Identities in the Intestinal Crypt Supports Stem Cell Function,” Nature 543, no. 7645 (2017): 424–427.

[305] J. H. van Es, K. Wiebrands, C. López-Iglesias, et al., “Enteroendocrine and Tuft Cells Support LGR5 Stem Cells on Paneth Cell Depletion,” Proceedings of the National Academy of Sciences 116, no. 52 (2019): 26599–26605.

[306] S. Fatrai, S. J. van Schelven, I. Ubink, et al., “Maintenance of Clonogenic KIT⁺ Human Colon Tumor Cells Requires Secretion of Stem Cell Factor by Differentiated Tumor Cells,” Gastroenterology 149, no. 3 (2015): 692–704.

[307] T. Cao, W. Zhang, Q. Wang, et al., “Cancer SLC6A6-Mediated Taurine Uptake Transactivates Immune Checkpoint Genes and Induces Exhaustion in CD8⁺ T Cells,” Cell 187, no. 9 (2024): 2288–2304.

[308] W. A. Flavahan, Q. Wu, M. Hitomi, et al., “Brain Tumor Initiating Cells Adapt to Restricted Nutrition Through Preferential Glucose Uptake,” Nature Neuroscience 16, no. 10 (2013): 1373–1382.

[309] J. Lu, X. Ye, F. Fan, et al., “Endothelial Cells Promote the Colorectal Cancer Stem Cell Phenotype Through a Soluble Form of Jagged-1,” Cancer Cell 23, no. 2 (2013): 171–185.

[310] M. Rathore, K. Curry, W. Huang, et al., “Leucine-Rich Alpha-2-Glycoprotein 1 Promotes Metastatic Colorectal Cancer Growth Through Human Epidermal Growth Factor Receptor 3 Signaling,” Gastroenterology 168, no. 2 (2024): 300–315.

[311] B. Beck, G. Driessens, S. Goossens, et al., “A Vascular Niche and a VEGF-Nrp1 Loop Regulate the Initiation and Stemness of Skin Tumours,” Nature 478, no. 7369 (2011): 399–403.

[312] Y.-F. Ping, X. Zhang, and X.-W. Bian, “Cancer Stem Cells and Their Vascular Niche: Do They Benefit From Each Other?,” Cancer Letters 380, no. 2 (2016): 561–567.

[313] W. Shangguan, C. Fan, X. Chen, et al., “Endothelium Originated From Colorectal Cancer Stem Cells Constitute Cancer Blood Vessels,” Cancer Science 108, no. 7 (2017): 1357–1367.

[314] E. Lizárraga-Verdugo, M. Avendaño-Félix, M. Bermúdez, R. Ramos-Payán, C. Pérez-Plasencia, and M. Aguilar-Medina, “Cancer Stem Cells and Its Role in Angiogenesis and Vasculogenic Mimicry in Gastrointestinal Cancers,” Frontiers in Oncology 10 (2020): 413.

[315] K. Tarao, A. Nozaki, T. Ikeda, et al., “Real Impact of Liver Cirrhosis on the Development of Hepatocellular Carcinoma in Various Liver Diseases-Meta-Analytic Assessment,” Cancer Medicine 8, no. 3 (2019): 1054–1065.

[316] E. Y. T. Lau, J. Lo, B. Y. L. Cheng, et al., “Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma Through c-Met/FRA1/HEY1 Signaling,” Cell Reports 15, no. 6 (2016): 1175–1189.

[317] H. Rhee, H.-Y. Kim, J.-H. Choi, et al., “Keratin 19 Expression in Hepatocellular Carcinoma Is Regulated by Fibroblast-Derived HGF via a MET-ERK1/2-AP1 and SP1 Axis,” Cancer Research 78, no. 7 (2018): 1619–1631.

[318] S. Xiong, R. Wang, Q. Chen, et al., “Cancer-Associated Fibroblasts Promote Stem Cell-Like Properties of Hepatocellular Carcinoma Cells Through IL-6/STAT3/Notch Signaling,” American Journal of Cancer Research 8, no. 2 (2018): 302–316.

[319] M. Song, J. He, Q.-Z. Pan, et al., “Cancer-Associated Fibroblast-Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma Progression,” Hepatology 73, no. 5 (2021): 1717–1735.

[320] C. Liu, L. Liu, X. Chen, et al., “LSD1 Stimulates Cancer-Associated Fibroblasts to Drive Notch3-Dependent Self-Renewal of Liver Cancer Stem-Like Cells,” Cancer Research 78, no. 4 (2018): 938–949.

[321] J. Jiang, F. Ye, X. Yang, et al., “Peri-Tumor Associated Fibroblasts Promote Intrahepatic Metastasis of Hepatocellular Carcinoma by Recruiting Cancer Stem Cells,” Cancer Letters 404 (2017): 19–28.

[322] Y. Xiao, P. Tao, K. Zhang, et al., “Myofibroblast-Derived Extracellular Vesicles Facilitate Cancer Stemness of Hepatocellular Carcinoma via Transferring ITGA5 to Tumor Cells,” Molecular Cancer 23 (2024): 262.

[323] J. Ji, T. Eggert, A. Budhu, et al., “Hepatic Stellate Cell and Monocyte Interaction Contributes to Poor Prognosis in Hepatocellular Carcinoma,” Hepatology 62, no. 2 (2015): 481–495.

[324] M. Roulis, A. Kaklamanos, M. Schernthanner, et al., “Paracrine Orchestration of Intestinal Tumorigenesis by a Mesenchymal Niche,” Nature 580, no. 7804 (2020): 524–529.

[325] Y.-A. Tang, Y. Chen, Y. Bao, et al., “Hypoxic Tumor Microenvironment Activates GLI2 via HIF-1α and TGF-Β2 to Promote Chemoresistance in Colorectal Cancer,” Proceedings of the National Academy of Sciences 115, no. 26 (2018): E5990–E5999.

[326] K. J. Lenos, D. M. Miedema, S. C. Lodestijn, et al., “Stem Cell Functionality Is Microenvironmentally Defined During Tumour Expansion and Therapy Response in Colon Cancer,” Nature Cell Biology 20, no. 10 (2018): 1193–1202.

[327] P. Nallasamy, R. K. Nimmakayala, S. Karmakar, et al., “Pancreatic Tumor Microenvironment Factor Promotes Cancer Stemness via SPP1-CD44 Axis,” Gastroenterology 161, no. 6 (2021): 1998–2013.

[328] N. Niu, X. Shen, Z. Wang, et al., “Tumor Cell-Intrinsic Epigenetic Dysregulation Shapes Cancer-Associated Fibroblasts Heterogeneity to Metabolically Support Pancreatic Cancer,” Cancer Cell 42, no. 5 (2024): 869–884.

[329] H. D. Reavis, H. I. Chen, and R. Drapkin, “Tumor Innervation: Cancer Has Some Nerve,” Trends in Cancer 6, no. 12 (2020): 1059–1067.

[330] R. Lu, C. Fan, W. Shangguan, et al., “Neurons Generated From Carcinoma Stem Cells Support Cancer Progression,” Signal Transduction and Targeted Therapy 2 (2017): 16036.

[331] Y. Hayakawa, K. Sakitani, M. Konishi, et al., “Nerve Growth Factor Promotes Gastric Tumorigenesis Through Aberrant Cholinergic Signaling,” Cancer Cell 31, no. 1 (2017): 21–34.

[332] B. W. Renz, R. Takahashi, T. Tanaka, et al., “Β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer,” Cancer Cell 33, no. 1 (2018): 75–90.

[333] M. Muñoz and R. Coveñas, “Neurokinin-1 Receptor Antagonists as Antitumor Drugs in Gastrointestinal Cancer: A New Approach,” Saudi Journal of Gastroenterology 22, no. 4 (2016): 260–268.

[334] P. Zhu, T. Lu, Z. Chen, et al., “5-Hydroxytryptamine Produced by Enteric Serotonergic Neurons Initiates Colorectal Cancer Stem Cell Self-Renewal and Tumorigenesis,” Neuron 110, no. 14 (2022): 2268–2282.

[335] Z. Firtina Karagonlar, D. Koç, E. Şahin, et al., “Effect of Adipocyte-Secreted Factors on EpCAM⁺/CD133⁺ Hepatic Stem Cell Population,” Biochemical and Biophysical Research Communications 474, no. 3 (2016): 482–490.

[336] D. B. Uthaya Kumar, C.-L. Chen, J.-C. Liu, et al., “TLR4 Signaling via NANOG Cooperates With STAT3 to Activate Twist1 and Promote Formation of Tumor-Initiating Stem-Like Cells in Livers of Mice,” Gastroenterology 150, no. 3 (2016): 707–719.

[337] S. Di Franco, P. Bianca, D. S. Sardina, et al., “Adipose Stem Cell Niche Reprograms the Colorectal Cancer Stem Cell Metastatic Machinery,” Nature Communications 12, no. 1 (2021): 5006.

[338] G. Li, J. E. Choi, I. Kryczek, et al., “Intersection of Immune and Oncometabolic Pathways Drives Cancer Hyperprogression During Immunotherapy,” Cancer Cell 41, no. 2 (2023): 304–322.

[339] Y. Kurebayashi, H. Ojima, H. Tsujikawa, et al., “Landscape of Immune Microenvironment in Hepatocellular Carcinoma and Its Additional Impact on Histological and Molecular Classification,” Hepatology 68, no. 3 (2018): 1025–1041.

[340] J. Agudo, E. S. Park, S. A. Rose, et al., “Quiescent Tissue Stem Cells Evade Immune Surveillance,” Immunity 48, no. 2 (2018): 271–285.

[341] J. Calderaro, F. Petitprez, E. Becht, et al., “Intra-Tumoral Tertiary Lymphoid Structures Are Associated With a Low Risk of Early Recurrence of Hepatocellular Carcinoma,” Journal of Hepatology 70, no. 1 (2019): 58–65.

[342] S. Finkin, D. Yuan, I. Stein, et al., “Ectopic Lymphoid Structures Function as Microniches for Tumor Progenitor Cells in Hepatocellular Carcinoma,” Nature Immunology 16, no. 12 (2015): 1235–1244.

[343] M. Meylan, F. Petitprez, L. Lacroix, et al., “Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules,” Clinical Cancer Research 26, no. 16 (2020): 4381–4389.

[344] T. K.-W. Lee, V. C.-H. Cheung, P. Lu, et al., “Blockade of CD47-Mediated Cathepsin S/Protease-Activated Receptor 2 Signaling Provides a Therapeutic Target for Hepatocellular Carcinoma,” Hepatology 60, no. 1 (2014): 179–191.

[345] J. Lo, E. Y. T. Lau, R. H. H. Ching, et al., “Nuclear Factor Kappa B-Mediated CD47 Up-Regulation Promotes Sorafenib Resistance and Its Blockade Synergizes the Effect of Sorafenib in Hepatocellular Carcinoma in Mice,” Hepatology 62, no. 2 (2015): 534–545.

[346] T. K. W. Lee, A. Castilho, V. C. H. Cheung, K. H. Tang, S. Ma, and I. O. L. Ng, “CD24⁺ Liver Tumor-Initiating Cells Drive Self-Renewal and Tumor Initiation Through STAT3-Mediated NANOG Regulation,” Cell Stem Cell 9, no. 1 (2011): 50–63.

[347] V. P. Sharma, B. Tang, Y. Wang, et al., “Live Tumor Imaging Shows Macrophage Induction and TMEM-Mediated Enrichment of Cancer Stem Cells During Metastatic Dissemination,” Nature Communications 12, no. 1 (2021): 7300.

[348] Y. Chen, H. Wen, C. Zhou, et al., “TNF-α Derived From M2 Tumor-Associated Macrophages Promotes Epithelial-Mesenchymal Transition and Cancer Stemness Through the Wnt/β-Catenin Pathway in SMMC-7721 Hepatocellular Carcinoma Cells,” Experimental Cell Research 378, no. 1 (2019): 41–50.

[349] Q.-M. Fan, Y.-Y. Jing, G.-F. Yu, et al., “Tumor-Associated Macrophages Promote Cancer Stem Cell-Like Properties via Transforming Growth Factor-Beta1-Induced Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma,” Cancer Letters 352, no. 2 (2014): 160–168.

[350] X.-T. Fu, Z. Dai, K. Song, et al., “Macrophage-Secreted IL-8 Induces Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Cells by Activating the JAK2/STAT3/Snail Pathway,” International Journal of Oncology 46, no. 2 (2015): 587–596.

[351] Y. Wang, B. Wang, S. Xiao, Y. Li, and Q. Chen, “miR-125a/b Inhibits Tumor-Associated Macrophages Mediated in Cancer Stem Cells of Hepatocellular Carcinoma by Targeting CD90,” Journal of Cellular Biochemistry 120, no. 3 (2019): 3046–3055.

[352] S.-L. Zhou, D. Yin, Z.-Q. Hu, et al., “A Positive Feedback Loop Between Cancer Stem-Like Cells and Tumor-Associated Neutrophils Controls Hepatocellular Carcinoma Progression,” Hepatology 70, no. 4 (2019): 1214–1230.

[353] D. J. Park, P. S. Sung, J.-H. Kim, et al., “EpCAM-High Liver Cancer Stem Cells Resist Natural Killer Cell-Mediated Cytotoxicity by Upregulating CEACAM1,” Journal for Immunotherapy of Cancer 8, no. 1 (2020): e000301.

[354] P. F. Y. Cheung, C. W. Yip, N. C. L. Wong, et al., “Granulin-Epithelin Precursor Renders Hepatocellular Carcinoma Cells Resistant to Natural Killer Cytotoxicity,” Cancer Immunology Research 2, no. 12 (2014): 1209–1219.

[355] C. Wang, W. Yang, H.-X. Yan, et al., “Hepatitis B Virus X (HBx) Induces Tumorigenicity of Hepatic Progenitor Cells in 3,5-Diethoxycarbonyl-1,4-Dihydrocollidine-Treated HBx Transgenic Mice,” Hepatology 55, no. 1 (2012): 108–120.

[356] H. Fan, H. Zhang, P. E. Pascuzzi, and O. Andrisani, “Hepatitis B Virus X Protein Induces EpCAM Expression via Active DNA Demethylation Directed by RelA in Complex With EZH2 and TET2,” Oncogene 35, no. 6 (2016): 715–726.

[357] C. Wang, M. Wang, P. Cheng, et al., “Hepatitis B Virus X Protein Promotes the Stem-Like Properties of OV6⁺ Cancer Cells in Hepatocellular Carcinoma,” Cell Death & Disease 8, no. 1 (2017): e2560.

[358] Z. Liu, X. Dai, T. Wang, et al., “Hepatitis B Virus PreS1 Facilitates Hepatocellular Carcinoma Development by Promoting Appearance and Self-Renewal of Liver Cancer Stem Cells,” Cancer Letters 400 (2017): 149–160.

[359] Y.-C. Kwon, S. K. Bose, R. Steele, et al., “Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes,” Journal of Virology 89, no. 22 (2015): 11549–11556.

[360] N. Ali, H. Allam, R. May, et al., “Hepatitis C Virus-Induced Cancer Stem Cell-Like Signatures in Cell Culture and Murine Tumor Xenografts,” Journal of Virology 85, no. 23 (2011): 12292–12303.

[361] E. Bessède, C. Staedel, L. A. Acuña Amador, et al., “Helicobacter pylori Generates Cells With Cancer Stem Cell Properties via Epithelial–Mesenchymal Transition-Like Changes,” Oncogene 33, no. 32 (2014): 4123–4131.

[362] Z. Chen, Z. Dong, H. Xiang, S. Chen, W. Yu, and C. Liang, “Helicobacter pylori CagA Protein Induces Gastric Cancer Stem Cell-Like Properties Through the Akt/FOXO3a Axis,” Journal of Cellular Biochemistry 125, no. 3 (2024): e30527.

[363] K. Guo, J. Duan, J. Lu, et al., “Tumor Necrosis Factor-α-Inducing Protein of Helicobacter pylori Promotes Epithelial-Mesenchymal Transition and Cancer Stem-Like Cells Properties via Activation of Wnt/β-Catenin Signaling Pathway in Gastric Cancer Cells,” Pathogens and Disease 80, no. 1 (2022): ftac025.

[364] M. Sigal, M. E. Rothenberg, C. Y. Logan, et al., “Helicobacter pylori Activates and Expands LGR5⁺ Stem Cells Through Direct Colonization of the Gastric Glands,” Gastroenterology 148, no. 7 (2015): 1392–1404.

[365] J. Wizenty, S. Müllerke, M. Kolesnichenko, et al., “Gastric Stem Cells Promote Inflammation and Gland Remodeling in Response to Helicobacter pylori via Rspo3-Lgr4 Axis,” EMBO Journal 41, no. 13 (2022): e109996.

[366] X. Yan, L. Liu, H. Li, H. Qin, and Z. Sun, “Clinical Significance of Fusobacterium nucleatum, Epithelial-Mesenchymal Transition, and Cancer Stem Cell Markers in Stage III/IV Colorectal Cancer Patients,” OncoTargets and Therapy 10 (2017): 5031–5046.

[367] Q. Wang, C. Yu, C. Yue, and X. Liu, “Fusobacterium nucleatum Produces Cancer Stem Cell Characteristics via EMT-Resembling Variations,” International Journal of Clinical and Experimental Pathology 13, no. 7 (2020): 1819–1828.

[368] M. R. Rubinstein, J. E. Baik, S. M. Lagana, et al., “Fusobacterium nucleatum Promotes Colorectal Cancer by Inducing Wnt/β-Catenin Modulator Annexin A1,” EMBO Reports 20, no. 4 (2019): e47638.

[369] M. R. Rubinstein, X. Wang, W. Liu, Y. Hao, G. Cai, and Y. W. Han, “Fusobacterium nucleatum Promotes Colorectal Carcinogenesis by Modulating E-Cadherin/β-Catenin Signaling via Its FadA Adhesin,” Cell Host & Microbe 14, no. 2 (2013): 195–206.

[370] H. Liu, J. Du, S. Chao, et al., “Fusobacterium nucleatum Promotes Colorectal Cancer Cell to Acquire Stem Cell-Like Features by Manipulating Lipid Droplet-Mediated Numb Degradation,” Advanced Science 9, no. 12 (2022): e2105222.

[371] Y. Okita, M. Koi, K. Takeda, et al., “Fusobacterium nucleatum Infection Correlates With Two Types of Microsatellite Alterations in Colorectal Cancer and Triggers DNA Damage,” Gut Pathogens 12 (2020): 46.

[372] J. Abed, J. E. M. Emgård, G. Zamir, et al., “Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc,” Cell Host & Microbe 20, no. 2 (2016): 215–225.

[373] C. Gur, Y. Ibrahim, B. Isaacson, et al., “Binding of the Fap2 Protein of Fusobacterium nucleatum to Human Inhibitory Receptor TIGIT Protects Tumors From Immune Cell Attack,” Immunity 42, no. 2 (2015): 344–355.

[374] A. D. Kostic, E. Chun, L. Robertson, et al., “Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment,” Cell Host & Microbe 14, no. 2 (2013): 207–215.

[375] J. L. Galeano Niño, H. Wu, K. D. LaCourse, et al., “Effect of the Intratumoral Microbiota on Spatial and Cellular Heterogeneity in Cancer,” Nature 611, no. 7937 (2022): 810–817.

[376] J. Sun, Q. Luo, L. Liu, and G. Song, “Low-Level Shear Stress Induces Differentiation of Liver Cancer Stem Cells via the Wnt/β-Catenin Signalling Pathway,” Experimental Cell Research 375, no. 1 (2019): 90–96.

[377] Y. You, Q. Zheng, Y. Dong, et al., “Matrix Stiffness-Mediated Effects on Stemness Characteristics Occurring in HCC Cells,” Oncotarget 7, no. 22 (2016): 32221–32231.

[378] O. Govaere, J. Wouters, M. Petz, et al., “Laminin-332 Sustains Chemoresistance and Quiescence as Part of the Human Hepatic Cancer Stem Cell Niche,” Journal of Hepatology 64, no. 3 (2016): 609–617.

[379] J. Schrader, T. T. Gordon-Walker, R. L. Aucott, et al., “Matrix Stiffness Modulates Proliferation, Chemotherapeutic Response, and Dormancy in Hepatocellular Carcinoma Cells,” Hepatology 53, no. 4 (2011): 1192–1205.

[380] B. Tian, Q. Luo, Y. Ju, and G. Song, “A Soft Matrix Enhances the Cancer Stem Cell Phenotype of HCC Cells,” International Journal of Molecular Sciences 20, no. 11 (2019): 2831.

[381] K.-Y. Ng, Q. T. Shea, T.-L. Wong, et al., “Chemotherapy-Enriched THBS2-Deficient Cancer Stem Cells Drive Hepatocarcinogenesis Through Matrix Softness Induced Histone H3 Modifications,” Advanced Science 8, no. 5 (2021): 2002483.

[382] K. Kohga, T. Tatsumi, T. Takehara, et al., “Expression of CD133 Confers Malignant Potential by Regulating Metalloproteinases in Human Hepatocellular Carcinoma,” Journal of Hepatology 52, no. 6 (2010): 872–879.

[383] Y. Chang, J. Zhang, X. Huo, et al., “Substrate Rigidity Dictates Colorectal Tumorigenic Cell Stemness and Metastasis via CRAD-Dependent Mechanotransduction,” Cell Reports 38, no. 7 (2022): 110390.

[384] W.-W. Tong, G.-H. Tong, and Y. Liu, “Cancer Stem Cells and Hypoxia-Inducible Factors (Review),” International Journal of Oncology 53, no. 2 (2018): 469–476.

[385] C. K. Lau, Z. F. Yang, D. W. Ho, et al., “An Akt/Hypoxia-Inducible Factor-1α/Platelet-Derived Growth Factor-BB Autocrine Loop Mediates Hypoxia-Induced Chemoresistance in Liver Cancer Cells and Tumorigenic Hepatic Progenitor Cells,” Clinical Cancer Research 15, no. 10 (2009): 3462–3471.

[386] C.-P. Cui, C. C.-L. Wong, A. K.-L. Kai, et al., “SENP1 Promotes Hypoxia-Induced Cancer Stemness by HIF-1α deSUMOylation and SENP1/HIF-1α Positive Feedback Loop,” Gut 66, no. 12 (2017): 2149–2159.

[387] J. H. C. Loong, T.-L. Wong, M. Tong, et al., “Glucose Deprivation-Induced Aberrant FUT1-Mediated Fucosylation Drives Cancer Stemness in Hepatocellular Carcinoma,” Journal of Clinical Investigation 131, no. 11 (2021): e143377.

[388] H.-L. Zhang, M.-D. Wang, X. Zhou, et al., “Blocking Preferential Glucose Uptake Sensitizes Liver Tumor-Initiating Cells to Glucose Restriction and Sorafenib Treatment,” Cancer Letters 388 (2017): 1–11.

[389] M. Shimizu and N. Tanaka, “IL-8-Induced O-Glcnac Modification via GLUT3 and GFAT Regulates Cancer Stem Cell-Like Properties in Colon and Lung Cancer Cells,” Oncogene 38, no. 9 (2019): 1520–1533.

[390] U. P. Yadav, T. Singh, P. Kumar, et al., “Metabolic Adaptations in Cancer Stem Cells,” Frontiers in Oncology 10 (2020): 1010.

[391] H. Zhao, C. Yan, Y. Hu, et al., “Differentiated Cancer Cell-Originated Lactate Promotes the Self-Renewal of Cancer Stem Cells in Patient-Derived Colorectal Cancer Organoids,” Cancer Letters 493 (2020): 236–244.

[392] S. Liu, H. Zhao, Y. Hu, et al., “Lactate Promotes Metastasis of Normoxic Colorectal Cancer Stem Cells Through PGC-1α-Mediated Oxidative Phosphorylation,” Cell Death & Disease 13, no. 7 (2022): 651.

[393] D. Zhang, Z. Tang, H. Huang, et al., “Metabolic Regulation of Gene Expression by Histone Lactylation,” Nature 574, no. 7779 (2019): 575–580.

[394] Z. Zong, F. Xie, S. Wang, et al., “Alanyl-tRNA Synthetase, AARS1, Is a Lactate Sensor and Lactyltransferase That Lactylates P53 and Contributes to Tumorigenesis,” Cell 187, no. 10 (2024): 2375–2392.

[395] H. Chen, Y. Li, H. Li, et al., “NBS1 Lactylation Is Required for Efficient DNA Repair and Chemotherapy Resistance,” Nature 631, no. 8021 (2024): 663–669.

[396] Y. Chen, J. Wu, L. Zhai, et al., “Metabolic Regulation of Homologous Recombination Repair by MRE11 Lactylation,” Cell 187, no. 2 (2024): 294–311.

[397] Y. He, Y. Ling, Z. Zhang, et al., “Butyrate Reverses Ferroptosis Resistance in Colorectal Cancer by Inducing C-Fos-Dependent xCT Suppression,” Redox Biology 65 (2023): 102822.

[398] V. Giroux and A. K. Rustgi, “Metaplasia: Tissue Injury Adaptation and a Precursor to the Dysplasia–Cancer Sequence,” Nature Reviews Cancer 17, no. 10 (2017): 594–604.

[399] L. Farhana, P. Nangia-Makker, E. Arbit, et al., “Bile Acid: A Potential Inducer of Colon Cancer Stem Cells,” Stem Cell Research & Therapy 7, no. 1 (2016): 181.

[400] T. Fu, S. Coulter, E. Yoshihara, et al., “FXR Regulates Intestinal Cancer Stem Cell Proliferation,” Cell 176, no. 5 (2019): 1098–1112.

[401] G. Sorrentino, A. Perino, E. Yildiz, et al., “Bile Acids Signal via TGR5 to Activate Intestinal Stem Cells and Epithelial Regeneration,” Gastroenterology 159, no. 3 (2020): 956–968.

[402] H. Zhang, H. Xu, C. Zhang, Q. Tang, and F. Bi, “Ursodeoxycholic Acid Suppresses the Malignant Progression of Colorectal Cancer Through TGR5-YAP Axis,” Cell Death Discovery 7, no. 1 (2021): 207.

[403] Y. Hayakawa, H. Ariyama, J. Stancikova, et al., “Mist1 Expressing Gastric Stem Cells Maintain the Normal and Neoplastic Gastric Epithelium and Are Supported by a Perivascular Stem Cell Niche,” Cancer Cell 28, no. 6 (2015): 800–814.

[404] H. Nienhüser, W. Kim, E. Malagola, et al., “Mist1+ Gastric Isthmus Stem Cells Are Regulated by Wnt5a and Expand in Response to Injury and Inflammation in Mice,” Gut 70, no. 4 (2021): 654–665.

[405] N. S. Münch, H.-Y. Fang, J. Ingermann, et al., “High-Fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett's Esophagus via Interleukin 8 and Alterations to the Gut Microbiome,” Gastroenterology 157, no. 2 (2019): 492–506.

[406] A. Mitra, J. Yan, X. Xia, et al., “IL6-Mediated Inflammatory Loop Reprograms Normal to Epithelial-Mesenchymal Transition+ Metastatic Cancer Stem Cells in Preneoplastic Liver of Transforming Growth Factor Beta-Deficient Β2-Spectrin+/− Mice,” Hepatology 65, no. 4 (2017): 1222–1236.

[407] S. H. Lee, H. S. Hong, Z. X. Liu, et al., “TNFα Enhances Cancer Stem Cell-Like Phenotype via Notch-Hes1 Activation in Oral Squamous Cell Carcinoma Cells,” Biochemical and Biophysical Research Communications 424, no. 1 (2012): 58–64.

[408] L. V. Kovtonyuk, F. Caiado, S. Garcia-Martin, et al., “IL-1 Mediates Microbiome-Induced Inflammaging of Hematopoietic Stem Cells in Mice,” Blood 139, no. 1 (2022): 44–58.

[409] Y.-X. Jiang, S.-W. Yang, P.-A. Li, et al., “The Promotion of the Transformation of Quiescent Gastric Cancer Stem Cells by IL-17 and the Underlying Mechanisms,” Oncogene 36, no. 9 (2017): 1256–1264.

[410] S. A. Melo, H. Sugimoto, J. T. O'Connell, et al., “Cancer Exosomes Perform Cell-Independent microRNA Biogenesis and Promote Tumorigenesis,” Cancer Cell 26, no. 5 (2014): 707–721.

[411] F. Zhong, X. Cheng, S. Sun, and J. Zhou, “Transcriptional Activation of PD-L1 by SoX2 Contributes to the Proliferation of Hepatocellular Carcinoma Cells,” Oncology Reports 37, no. 5 (2017): 3061–3067.

[412] P. Xiao, X. Long, L. Zhang, et al., “Neurotensin/IL-8 Pathway Orchestrates Local Inflammatory Response and Tumor Invasion by Inducing M2 Polarization of Tumor-Associated Macrophages and Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells,” Oncoimmunology 7, no. 7 (2018): e1440166.

[413] S. Taniguchi, A. Elhance, A. Van Duzer, S. Kumar, J. J. Leitenberger, and N. Oshimori, “Tumor-Initiating Cells Establish an IL-33-TGF-β Niche Signaling Loop to Promote Cancer Progression,” Science 369, no. 6501 (2020): eaay1813.

[414] L. Ren, Y. Yu, L. Wang, Z. Zhu, R. Lu, and Z. Yao, “Hypoxia-Induced CCL28 Promotes Recruitment of Regulatory T Cells and Tumor Growth in Liver Cancer,” Oncotarget 7, no. 46 (2016): 75763–75773.

[415] P. Yang, Q.-J. Li, Y. Feng, et al., “TGF-β-miR-34a-CCL22 Signaling-Induced Treg Cell Recruitment Promotes Venous Metastases of HBV-Positive Hepatocellular Carcinoma,” Cancer Cell 22, no. 3 (2012): 291–303.

[416] W.-L. Hwang, H.-Y. Lan, W.-C. Cheng, S.-C. Huang, and M.-H. Yang, “Tumor Stem-Like Cell-Derived Exosomal RNAs Prime Neutrophils for Facilitating Tumorigenesis of Colon Cancer,” Journal of Hematology & Oncology 12, no. 1 (2019): 10.

[417] E. C. Madden, A. M. Gorman, S. E. Logue, and A. Samali, “Tumour Cell Secretome in Chemoresistance and Tumour Recurrence,” Trends in Cancer 6, no. 6 (2020): 489–505.

[418] L. Ricci-Vitiani, R. Pallini, M. Biffoni, et al., “Tumour Vascularization via Endothelial Differentiation of Glioblastoma Stem-Like Cells,” Nature 468, no. 7325 (2010): 824–828.

[419] R. Wang, K. Chadalavada, J. Wilshire, et al., “Glioblastoma Stem-Like Cells Give Rise to Tumour Endothelium,” Nature 468, no. 7325 (2010): 829–833.

[420] K. Liu, M. Hao, Y. Ouyang, J. Zheng, and D. Chen, “CD133⁺ Cancer Stem Cells Promoted by VEGF Accelerate the Recurrence of Hepatocellular Carcinoma,” Scientific Reports 7 (2017): 41499.

[421] J. Zhang, J. Fan, X. Zeng, et al., “Hedgehog Signaling in Gastrointestinal Carcinogenesis and the Gastrointestinal Tumor Microenvironment,” Acta Pharmaceutica Sinica B 11, no. 3 (2021): 609–620.

[422] H. Peinado, H. Zhang, I. R. Matei, et al., “Pre-Metastatic Niches: Organ-Specific Homes for Metastases,” Nature Reviews Cancer 17, no. 5 (2017): 302–317.

[423] T. R. Cox, R. M. H. Rumney, E. M. Schoof, et al., “Retracted Article: The Hypoxic Cancer Secretome Induces Pre-Metastatic Bone Lesions Through Lysyl Oxidase,” Nature 522, no. 7554 (2015): 106–110.

[424] G. Chen, A. C. Huang, W. Zhang, et al., “Exosomal PD-L1 Contributes to Immunosuppression and Is Associated With Anti-PD-1 Response,” Nature 560, no. 7718 (2018): 382–386.

[425] K. J. Hiam-Galvez, B. M. Allen, and M. H. Spitzer, “Systemic Immunity in Cancer,” Nature Reviews Cancer 21, no. 6 (2021): 345–359.

[426] D. Ternes, M. Tsenkova, V. I. Pozdeev, et al., “The Gut Microbial Metabolite Formate Exacerbates Colorectal Cancer Progression,” Nature Metabolism 4, no. 4 (2022): 458–475.

[427] L. Pöltl, M. Kitsera, S. Raffl, et al., “Microbiota-Derived Genotoxin Tilimycin Generates Colonic Stem Cell Mutations,” Cell Reports 42, no. 3 (2023): 112199.

[428] A. Belcheva, T. Irrazabal, S. J. Robertson, et al., “Gut Microbial Metabolism Drives Transformation of MSH2-Deficient Colon Epithelial Cells,” Cell 158, no. 2 (2014): 288–299.

[429] R. Malaguarnera and A. Belfiore, “The Emerging Role of Insulin and Insulin-Like Growth Factor Signaling in Cancer Stem Cells,” Frontiers in Endocrinology 5 (2014): 10.

[430] J.-S. Lee, M. W. Lero, J. Mercado-Matos, et al., “The Insulin and IGF Signaling Pathway Sustains Breast Cancer Stem Cells by IRS2/PI3K-Mediated Regulation of MYC,” Cell Reports 41, no. 10 (2022): 111759.

[431] J. C. Quintero, N. F. Díaz, M. Rodríguez-Dorantes, and I. Camacho-Arroyo, “Cancer Stem Cells and Androgen Receptor Signaling: Partners in Disease Progression,” International Journal of Molecular Sciences 24, no. 20 (2023): 15085.

[432] M. Mizuno, B. Khaledian, M. Maeda, et al., “Adipsin-Dependent Secretion of Hepatocyte Growth Factor Regulates the Adipocyte-Cancer Stem Cell Interaction,” Cancers 13, no. 16 (2021): 4238.

[433] Ö. H. Yilmaz, P. Katajisto, D. W. Lamming, et al., “mTORC1 in the Paneth Cell Niche Couples Intestinal Stem-Cell Function to Calorie Intake,” Nature 486, no. 7404 (2012): 490–495.

[434] A. Aliluev, S. Tritschler, M. Sterr, et al., “Diet-Induced Alteration of Intestinal Stem Cell Function Underlies Obesity and Prediabetes in Mice,” Nature Metabolism 3, no. 9 (2021): 1202–1216.

[435] C.-W. Cheng, M. Biton, A. L. Haber, et al., “Ketone Body Signaling Mediates Intestinal Stem Cell Homeostasis and Adaptation to Diet,” Cell 178, no. 5 (2019): 1115–1131.

[436] X. Zhang, O. O. Coker, E. S. Chu, et al., “Dietary Cholesterol Drives Fatty Liver-Associated Liver Cancer by Modulating Gut Microbiota and Metabolites,” Gut 70, no. 4 (2021): 761–774.

[437] R. Pallavi, E. Gatti, T. Durfort, et al., “Caloric Restriction Leads to Druggable LSD1-Dependent Cancer Stem Cells Expansion,” Nature Communications 15, no. 1 (2024): 828.

[438] S. Imada, S. Khawaled, H. Shin, et al., “Short-Term Post-Fast Refeeding Enhances Intestinal Stemness via Polyamines,” Nature 633, no. 8031 (2024): 895–904.

[439] P. A. Wood, X. Yang, A. Taber, et al., “Period 2 Mutation Accelerates ApcMin/+ Tumorigenesis,” Molecular Cancer Research 6, no. 11 (2008): 1786–1793.

[440] Z. Diamantopoulou, F. Castro-Giner, F. D. Schwab, et al., “The Metastatic Spread of Breast Cancer Accelerates During Sleep,” Nature 607, no. 7917 (2022): 156–162.

[441] X. Zhu, Y. Suo, Y. Fu, et al., “In Vivo Flow Cytometry Reveals a Circadian Rhythm of Circulating Tumor Cells,” Light: Science & Applications 10, no. 1 (2021): 110.

[442] C. Wang, Q. Zeng, Z. M. Gül, et al., “Circadian Tumor Infiltration and Function of CD8⁺ T Cells Dictate Immunotherapy Efficacy,” Cell 187, no. 11 (2024): 2690–2702.

[443] Y. Wang, R. Narasimamurthy, M. Qu, et al., “Circadian Regulation of Cancer Stem Cells and the Tumor Microenvironment during Metastasis,” Nature Cancer 5, no. 4 (2024): 546–556.

[444] H. Yang, L. Xia, J. Chen, et al., “Stress-Glucocorticoid-TSC22D3 Axis Compromises Therapy-Induced Antitumor Immunity,” Nature Medicine 25, no. 9 (2019): 1428–1441.

[445] Z. Wang, S. Y. Kim, W. Tu, et al., “Extracellular Vesicles in Fatty Liver Promote a Metastatic Tumor Microenvironment,” Cell Metabolism 35, no. 7 (2023): 1209–1226.

[446] N. S. Wilcox, U. Amit, J. B. Reibel, E. Berlin, K. Howell, and B. Ky, “Cardiovascular Disease and Cancer: Shared Risk Factors and Mechanisms,” Nature Reviews Cardiology 21, no. 9 (2024): 617–631.

[447] R. Ruze, J. Song, X. Yin, et al., “Mechanisms of Obesity- and Diabetes Mellitus-Related Pancreatic Carcinogenesis: A Comprehensive and Systematic Review,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 139.

[448] S. Zhu, T. Zhang, L. Zheng, et al., “Combination Strategies to Maximize the Benefits of Cancer Immunotherapy,” Journal of Hematology & Oncology 14, no. 1 (2021): 156.

[449] C. Nong, P. Guan, L. Li, H. Zhang, and H. Hu, “Tumor Immunotherapy: Mechanisms and Clinical Applications,” MedComm – Oncology 1, no. 1 (2022): e8.

[450] A. D. Waldman, J. M. Fritz, and M. J. Lenardo, “A Guide to Cancer Immunotherapy: From T Cell Basic Science to Clinical Practice,” Nature Reviews Immunology 20, no. 11 (2020): 651–668.

[451] C. W. Menke-van der Houven van Oordt, C. Gomez-Roca, C. van Herpen, et al., “First-in-Human Phase I Clinical Trial of RG7356, an Anti-CD44 Humanized Antibody, in Patients With Advanced, CD44-Expressing Solid Tumors,” Oncotarget 7, no. 48 (2016): 80046–80058.

[452] H. Lindhofer, A. Schoberth, D. Pelster, J. Hess, J. Herold, and M. Jäger, “Elimination of Cancer Stem Cells (CD133+/EpCAM+) From Malignant Ascites by the Trifunctional Antibody Catumaxomab: Results From a Pivotal Phase II/III Study,” Journal of Clinical Oncology 27, no. 15_suppl (2009): 3014.

[453] L. Zhao, Y. Yang, P. Zhou, et al., “Targeting CD133 High Colorectal Cancer Cells In Vitro and In Vivo With an Asymmetric Bispecific Antibody,” Journal of Immunotherapy 38, no. 6 (2015): 217–228.

[454] J. Huang, C. Li, Y. Wang, et al., “Cytokine-Induced Killer (CIK) Cells Bound With Anti-CD3/Anti-CD133 Bispecific Antibodies Target CD133(High) Cancer Stem Cells In Vitro and In Vivo,” Clinical Immunology 149, no. 1 (2013): 156–168.

[455] E. E. Storm, S. Durinck, F. de Sousa e Melo, et al., “Targeting PTPRK-RSPO3 Colon Tumours Promotes Differentiation and Loss of Stem-Cell Function,” Nature 529, no. 7584 (2016): 97–100.

[456] M. R. Junttila, W. Mao, X. Wang, et al., “Targeting LGR5⁺ Cells With an Antibody-Drug Conjugate for the Treatment of Colon Cancer,” Science Translational Medicine 7, no. 314 (2015): 314ra186.

[457] Y. Mi, Y. Huang, and J. Deng, “The Enhanced Delivery of Salinomycin to CD133⁺ Ovarian Cancer Stem Cells Through CD133 Antibody Conjugation With Poly(Lactic-Co-Glycolic Acid)-Poly(Ethylene Glycol) Nanoparticles,” Oncology Letters 15, no. 5 (2018): 6611–6621.

[458] Y. Liu, X. Yao, C. Wang, et al., “Peptide-Based 68Ga-PET Radiotracer for Imaging CD133 Expression in Colorectal Cancer,” Nuclear Medicine Communications 42, no. 10 (2021): 1144–1150.

[459] Y.-B. Zheng, J.-H. Gong, X.-J. Liu, Y. Li, and Y.-S. Zhen, “A CD13-Targeting Peptide Integrated Protein Inhibits Human Liver Cancer Growth by Killing Cancer Stem Cells and Suppressing Angiogenesis,” Molecular Carcinogenesis 56, no. 5 (2017): 1395–1404.

[460] P. Vora, C. Venugopal, S. K. Salim, et al., “The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma,” Cell Stem Cell 26, no. 6 (2020): 832–844.

[461] J.-Y. Kim, H.-Y. Lee, K.-K. Park, Y.-K. Choi, J.-S. Nam, and I.-S. Hong, “CWP232228 Targets Liver Cancer Stem Cells Through Wnt/β-Catenin Signaling: A Novel Therapeutic Approach for Liver Cancer Treatment,” Oncotarget 7, no. 15 (2016): 20395–20409.

[462] J. E. Frampton and N. Basset-Séguin, “Vismodegib: A Review in Advanced Basal Cell Carcinoma,” Drugs 78, no. 11 (2018): 1145–1156.

[463] J. U. Marquardt, L. Gomez-Quiroz, L. O. Arreguin Camacho, et al., “Curcumin Effectively Inhibits Oncogenic NF-κB Signaling and Restrains Stemness Features in Liver Cancer,” Journal of Hepatology 63, no. 3 (2015): 661–669.

[464] C. Liu, J. Qiang, Q. Deng, et al., “ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression,” Cancer Research 81, no. 23 (2021): 5919–5934.

[465] D. Xiang, Z. Cheng, H. Liu, et al., “Shp2 Promotes Liver Cancer Stem Cell Expansion by Augmenting β-Catenin Signaling and Predicts Chemotherapeutic Response of Patients,” Hepatology 65, no. 5 (2017): 1566–1580.

[466] C. O. N. Leung, M. Tong, K. P. S. Chung, et al., “Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma,” Hepatology 72, no. 1 (2020): 155–168.

[467] X.-D. Yang, F.-E. Kong, L. Qi, et al., “PARP Inhibitor Olaparib Overcomes Sorafenib Resistance Through Reshaping the Pluripotent Transcriptome in Hepatocellular Carcinoma,” Molecular Cancer 20, no. 1 (2021): 20.

[468] Y. Zhang, D. Guan, J. Shi, et al., “All-Trans Retinoic Acid Potentiates the Chemotherapeutic Effect of Cisplatin by Inducing Differentiation of Tumor Initiating Cells in Liver Cancer,” Journal of Hepatology 59, no. 6 (2013): 1255–1263.

[469] J. L. Tan, F. Li, J. Z. Yeo, et al., “New High-Throughput Screening Identifies Compounds That Reduce Viability Specifically in Liver Cancer Cells That Express High Levels of SALL4 by Inhibiting Oxidative Phosphorylation,” Gastroenterology 157, no. 6 (2019): 1615–1629.

[470] T. K. W. Lee, A. Castilho, V. C. H. Cheung, K. H. Tang, S. Ma, and I. O. L. Ng, “Lupeol Targets Liver Tumor-Initiating Cells Through Phosphatase and Tensin Homolog Modulation,” Hepatology 53, no. 1 (2011): 160–170.

[471] R. Wu, R. Murali, Y. Kabe, et al., “Baicalein Targets GTPase-Mediated Autophagy to Eliminate Liver Tumor-Initiating Stem Cell-Like Cells Resistant to mTORC1 Inhibition,” Hepatology 68, no. 5 (2018): 1726–1740.

[472] D. Li, X. Guo, K. Yang, et al., “EpCAM-Targeting CAR-T Cell Immunotherapy Is Safe and Efficacious for Epithelial Tumors,” Science Advances 9, no. 48 (2023): eadg9721.

[473] H. Dai, C. Tong, D. Shi, et al., “Efficacy and Biomarker Analysis of CD133-Directed CAR T Cells in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Trial,” Oncoimmunology 9, no. 1 (2020): 1846926.

[474] R. Vij, R. Nath, D. E. H. Afar, et al., “First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients With Relapsed and Refractory Multiple Myeloma,” Clinical Cancer Research 26, no. 10 (2020): 2308–2317.

[475] T. Else, E. Jonasch, O. Iliopoulos, et al., “Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study,” Clinical Cancer Research 30, no. 9 (2024): 1750–1757.

[476] C. Gridelli, T. Ciuleanu, M. Domine, et al., “Clinical Activity of a Htert (vx-001) Cancer Vaccine as Post-Chemotherapy Maintenance Immunotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Final Results of a Randomised Phase 2 Clinical Trial,” British Journal of Cancer 122, no. 10 (2020): 1461–1466.

[477] A. R. Rappaport, C. Kyi, M. Lane, et al., “A Shared Neoantigen Vaccine Combined With Immune Checkpoint Blockade for Advanced Metastatic Solid Tumors: Phase 1 Trial Interim Results,” Nature Medicine 30, no. 4 (2024): 1013–1022.

[478] S. Koido, J. Taguchi, M. Shimabuku, et al., “Dendritic Cells Pulsed With Multifunctional Wilms' Tumor 1 (WT1) Peptides Combined With Multiagent Chemotherapy Modulate the Tumor Microenvironment and Enable Conversion Surgery in Pancreatic Cancer,” Journal for Immunotherapy of Cancer 12, no. 10 (2024): e009765.

[479] A. Santoro, T. Pressiani, G. Citterio, et al., “Activity and Safety of NGR-hTNF, a Selective Vascular-Targeting Agent, in Previously Treated Patients With Advanced Hepatocellular Carcinoma,” British Journal of Cancer 103, no. 6 (2010): 837–844.

[480] D. Chen, B. Zou, B. Li, et al., “Adebrelimab Plus Chemotherapy and Sequential Thoracic Radiotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer (ES-SCLC): A Phase II Trial,” EClinicalMedicine 75 (2024): 102795.

[481] D. Liu, J. Gong, M. Liu, et al., “Phase I Study of BC001, a Novel Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2, in Advanced Solid Tumors,” Cancer Medicine 13, no. 22 (2024): e70208.

[482] V. Boni, M. J. Fidler, H.-T. Arkenau, et al., “Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors: An Open-Label Phase I/II Trial,” Clinical Cancer Research 28, no. 10 (2022): 2020–2029.

[483] S. Pant, Z. A. Wainberg, C. D. Weekes, et al., “Lymph-Node-Targeted, mkRAS-Specific Amphiphile Vaccine in Pancreatic and Colorectal Cancer: The Phase 1 AMPLIFY-201 Trial,” Nature Medicine 30, no. 2 (2024): 531–542.

[484] S. K. Swaminathan, E. Roger, U. Toti, L. Niu, J. R. Ohlfest, and J. Panyam, “CD133-Targeted Paclitaxel Delivery Inhibits Local Tumor Recurrence in a Mouse Model of Breast Cancer,” Journal of Controlled Release 171, no. 3 (2013): 280–287.

[485] E. Sangiorgi and M. R. Capecchi, “Bmi1 Is Expressed In Vivo in Intestinal Stem Cells,” Nature Genetics 40, no. 7 (2008): 915–920.

[486] C. Saygin, D. Matei, R. Majeti, O. Reizes, and J. D. Lathia, “Targeting Cancer Stemness in the Clinic: From Hype to Hope,” Cell Stem Cell 24, no. 1 (2019): 25–40.

[487] N. Badrinath and S. Y. Yoo, “Recent Advances in Cancer Stem Cell-Targeted Immunotherapy,” Cancers 11, no. 3 (2019): 310.

[488] J. Sun, K. Pan, M. Chen, et al., “Dendritic Cells-Mediated CTLs Targeting Hepatocellular Carcinoma Stem Cells,” Cancer Biology & Therapy 10, no. 4 (2010): 368–375.

[489] Y. J. Choi, S.-J. Park, Y.-S. Park, H. S. Park, K. M. Yang, and K. Heo, “EpCAM Peptide-Primed Dendritic Cell Vaccination Confers Significant Anti-Tumor Immunity in Hepatocellular Carcinoma Cells,” PLoS One 13, no. 1 (2018): e0190638.

[490] Y. Wang, M. Chen, Z. Wu, et al., “CD133-Directed CAR T Cells for Advanced Metastasis Malignancies: A Phase I Trial,” Oncoimmunology 7, no. 7 (2018): e1440169.

[491] A. M. Nicolas, M. Pesic, E. Engel, et al., “Inflammatory Fibroblasts Mediate Resistance to Neoadjuvant Therapy in Rectal Cancer,” Cancer Cell 40, no. 2 (2022): 168–184.

[492] F. E. M. Froeling, C. Feig, C. Chelala, et al., “Retinoic Acid-Induced Pancreatic Stellate Cell Quiescence Reduces Paracrine Wnt-β-Catenin Signaling to Slow Tumor Progression,” Gastroenterology 141, no. 4 (2011): 1486–1497.

[493] H. Xu, H. Luo, J. Zhang, K. Li, and M.-H. Lee, “Therapeutic Potential of Clostridium Butyricum Anticancer Effects in Colorectal Cancer,” Gut Microbes 15, no. 1 (2023): 2186114.

[494] L. Chen, J. Shen, Z. Kang, et al., “Fusobacterium nucleatum-Mimicking Nanovehicles to Overcome Chemoresistance for Breast Cancer Treatment by Eliminating Tumor-Colonizing Bacteria,” Chem 10, no. 6 (2024): 1783–1803.

[495] T. Shi, Y. Ma, L. Yu, et al., “Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints,” International Journal of Molecular Sciences 19, no. 5 (2018): 1389.

[496] P. J. Asif, C. Longobardi, M. Hahne, and J. P. Medema, “The Role of Cancer-Associated Fibroblasts in Cancer Invasion and Metastasis,” Cancers 13, no. 18 (2021): 4720.

[497] H. Wang, R. Wang, K. Cai, et al., “Selective in Vivo Metabolic Cell-Labeling-Mediated Cancer Targeting,” Nature Chemical Biology 13, no. 4 (2017): 415–424.

[498] Y. Bo, J. Zhou, K. Cai, et al., “Leveraging Intracellular ALDH1A1 Activity for Selective Cancer Stem-Like Cell Labeling and Targeted Treatment via in Vivo Click Reaction,” Proceedings of the National Academy of Sciences 120, no. 36 (2023): e2302342120.

[499] P. Kesharwani, R. Chadar, A. Sheikh, W. Y. Rizg, and A. Y. Safhi, “CD44-Targeted Nanocarrier for Cancer Therapy,” Frontiers in Pharmacology 12 (2021): 800481.

[500] S. Shen, X. Xu, S. Lin, et al., “A Nanotherapeutic Strategy to Overcome Chemotherapeutic Resistance of Cancer Stem-Like Cells,” Nature Nanotechnology 16, no. 1 (2021): 104–113.

[501] B. Herpers, B. Eppink, M. I. James, et al., “Functional Patient-Derived Organoid Screenings Identify MCLA-158 as a Therapeutic EGFR × LGR5 Bispecific Antibody With Efficacy in Epithelial Tumors,” Nature Cancer 3, no. 4 (2022): 418–436.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm – Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).